




CANCER INCIDENCE & MORTALITY DATA SRI LANKA 2021



Sri Lanka Cancer Registry
23rd Publication



2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021



NATIONAL CANCER CONTROL PROGRAMME
Ministry of Health



National Cancer Incidence and Mortality Data Sri Lanka 2021



National Cancer Control Programme
Elvitigala Mawatha
555, Public Health Complex
Narahenpita, Colombo 5
Sri Lanka

23rd Publication – National Cancer Incidence and Mortality Data Sri Lanka: 2021
Published in December 2023
ISBN No. 978-624-6511-04-3

Compiled by

Strategic Information Management (SIM) Unit
National Cancer Control Programme
Ministry of Health

Published by



National Cancer Control Programme
Ministry of Health
555/5 Public Health Complex
Elvitigala Mawatha
Narahenpita, Colombo 05
Sri Lanka

Contact No +94 112368627, Fax +94 112368627
Email- nccpsl@yahoo.com
Web – www.nccp.health.gov.lk

 National Cancer Control Programme, Sri Lanka

Printed by:

Selacine Media Solution
No. 380/57, Sarana Road,
Colombo 07

Table of Contents

	Page No.
Table of contents	iii
List of tables	iv
List of figures	vi
Message from the Director General of Health Services	ix
Message from the Deputy Director General, Non- Communicable Disease	xi
Foreword from Director, National Cancer Control Programme	xiii
List of contributors	xv
List of Acknowledgement	xvi
Executive summary	1
Introduction	5
Methodology	6
Cancer incidence data of Sri Lanka - 2021	12
Cancer mortality data of Sri Lanka	105
Statistical terminology	116
List of references	118

List of Tables

Table No	Description	Page No
Table 1 :	Distribution of government cancer treatment centres in year 2021	7
Table 2 :	Distribution of pathology laboratories which sent details of newly diagnosed cancer patients in year 2021	8
Table 3 :	Distribution of OMF Units which sent details of newly diagnosed cancer patients in year 2021	9
Table 4 :	Estimated mid-year population by five-year age groups in Sri Lanka, 2021	10
Table 5 :	Estimated mid-year population by district in Sri Lanka, 2021	11
Table 6 :	Cancer Incidence by sex in Sri Lanka, 2005- 2021	13
Table 7 :	Cancer Incidence by five-year age groups and sex in Sri Lanka, 2021	15
Table 8 :	Leading cancer site by sex in Sri Lanka, 2021	16
Table 9 :	Number of cancers by five-year age groups and ICD 10 site, among males in Sri Lanka, 2021	24
Table 10 :	Number of cancers by five-year age groups and ICD 10 site, among females in Sri Lanka, 2021	26
Table 11 :	Number of cancers by five-year age group and ICD 10 site categories among males in Sri Lanka, 2021	28
Table 12 :	Number of Cancers by five-year age group and ICD 10 site categories among females in Sri Lanka, 2021	29
Table 13 :	Age Specific Incidence Rate, Crude Incidence Rate, Age Standardized Incidence Rate per 100 000 population and Cumulative Risk of cancers by five – Year age group and ICD 10 site categories among Males in Sri Lanka, 2021	30
Table 14 :	Age Specific Incidence Rate, Crude Incidence Rate, Age Standardized Incidence Rate per 100 000 population and Cumulative Risk of cancers by five – Year age group and ICD 10 site categories among Females in Sri Lanka, 2021	31
Table 15 :	Lip, tongue, and mouth cancer incidence data in Sri Lanka, 2021	32
Table 16 :	Pharyngeal cancer incidence data in Sri Lanka, 2021	35
Table 17 :	Oesophageal cancer incidence data in Sri Lanka, 2021	38
Table 18 :	Stomach cancer incidence data in Sri Lanka, 2021	40
Table 19 :	Colon and rectum cancer incidence data in Sri Lanka, 2021	42
Table 20 :	Laryngeal cancer incidence data in Sri Lanka, 2021	45
Table 21 :	Trachea, bronchus and lung cancer incidence data in Sri Lanka, 2021	47
Table 22 :	Skin cancer incidence data in Sri Lanka, 2021	50

List of Tables

Table No	Description	Page No
Table 23 :	Breast cancer incidence data in Sri Lanka, 2021	53
Table 24 :	Cervix Uteri cancer incidence data in Sri Lanka, 2021	56
Table 25 :	Uterine cancer incidence data in Sri Lanka, 2021	58
Table 26 :	Ovary cancer incidence in Sri Lanka, 2021	61
Table 27 :	Prostate cancer incidence data in Sri Lanka, 2021	64
Table 28 :	Urinary bladder cancer incidence data in Sri Lanka, 2021	66
Table 29 :	Thyroid gland cancer incidence data in Sri Lanka, 2021	68
Table 30 :	Lymphoma incidence data in Sri Lanka, 2021	70
Table 31 :	Leukaemia incidence data in Sri Lanka, 2021	73
Table 32 :	Basis of diagnosis of cancer patients in Sri Lanka, 2021	77
Table 33 :	Childhood and adolescent cancer incidence data (0-19 years) in Sri Lanka, 2021	79
Table 34 :	Overall, cancer Incidence by province and district in Sri Lanka, 2021	85
Table 35 :	Leading cancer incidence data by sex and district in Sri Lanka, 2021	86
Table 36 :	Deaths due to neoplasms out of all deaths reported to vital registration system of Sri Lanka, 2001 – 2021	105
Table 37:	Deaths due to neoplasms by sex out of all deaths reported to vital registration system of Sri Lanka, 2001 – 2021	106
Table 38 :	Number of deaths and Crude Death Rates due to cancers by sex and site of cancer based on deaths reported to vital registration system of Sri Lanka 2019	108
Table 39 :	Deaths due to cancers among males and females in hospitals in Sri Lanka, 2005-2021	113
Table 40 :	Deaths due to cancers in hospitals, crude hospital annual death rates due to cancers and proportionate mortality ratio for cancers out of all hospital deaths in Sri Lanka, 2005-2021	114
Table 41 :	Hospitalizations, hospital deaths and case fatality rate due to cancers in year 2021 by RDHS divisions in Sri Lanka	115

List of Figures

Figure No	Description	Page No
Figure 1 :	Flow diagram of the process of cancer registration in Sri Lanka	06
Figure 2 :	Population pyramid of Sri Lanka in 2021 by five- year age groups	12
Figure 3 :	Crude Cancer Incidence Rates of Sri Lanka, 2005-2021	14
Figure 4 :	Age Standardized Cancer Incidence Rates of Sri Lanka, 2005-2021	14
Figure 5 :	Cancer Incidence Rates of Sri Lanka in 2021	15
Figure 6 :	Age Specific Cancer Rates Sri Lanka, 2021	16
Figure 7 :	Proportion of leading cancers in males in Sri Lanka, 2021	17
Figure 8 :	Proportion of leading cancers in females in Sri Lanka, 2021	17
Figure 9 :	Crude incidence rates of leading cancers in males in Sri Lanka, 2021	18
Figure 10:	Crude incidence rates of leading cancers in females in Sri Lanka, 2021	18
Figure 11:	Leading cancer by 00 – 14 age group among males in Sri Lanka, 2021	19
Figure 12:	Leading cancer by 00 – 14 age group among females in Sri Lanka, 2021	19
Figure 13:	Leading cancer by 15-34 age group among males in Sri Lanka, 2021	20
Figure 14:	Leading cancer by 15-34 age group among females in Sri Lanka, 2021	20
Figure 15:	Leading cancer by 35–49 age group among males in Sri Lanka, 2021	21
Figure 16:	Leading cancer by 35–49 age group among females in Sri Lanka, 2021	21
Figure 17:	Leading cancer by 50 – 64 age group among males in Sri Lanka, 2021	22
Figure 18:	Leading cancer by 50 – 64 age group among females in Sri Lanka, 2021	22
Figure 19:	Leading cancer by 65 years and above age group among males in Sri Lanka, 2021	23
Figure 20:	Leading cancer by 65 years and above age group among females in Sri Lanka, 2021	23
Figure 21:	Age Specific Rates of Lip, tongue and mouth cancer in Sri Lanka, 2021	34
Figure 22:	Age Standardized Incidence Rates of Lip, tongue and mouth cancer in Sri Lanka, 2005-2021	34
Figure 23:	Age Specific Incidence Rate of Pharyngeal cancer in Sri Lanka, 2021	37
Figure 24:	Age Standardized Incidence Rates of Pharyngeal cancer in Sri Lanka, 2012-2021	37
Figure 25:	Age Specific Incidence Rates of Oesophageal cancer in Sri Lanka, 2021	39
Figure 26:	Age Standardized Incidence Rates of Oesophageal cancer in Sri Lanka, 2005-2021	39
Figure 27:	Age Specific Incidence Rates of Stomach cancer in Sri Lanka, 2021	41

List of Figures

Figure No	Description	Page No
Figure 28:	Age Standardized Incidence Rates of Stomach cancer in Sri Lanka, 2005-2021	41
Figure 29:	Age Specific Incidence Rates of Colon and rectum cancer in Sri Lanka, 2021	44
Figure 30:	Age Standardized Incidence Rates of Colon and rectum cancer in Sri Lanka, 2005-2021	44
Figure 31:	Age Specific Incidence Rates of Laryngeal cancer in Sri Lanka, 2021	46
Figure 32:	Age Standardized Incidence Rates of Laryngeal cancer in Sri Lanka, 2005-2021	46
Figure 33:	Age Specific Incidence Rates of Trachea, bronchial and lung cancer in Sri Lanka, 2021	49
Figure 34:	Age Standardized Incidence Rates of Trachea, bronchial and lung cancer in Sri Lanka, 2005 - 2021	49
Figure 35:	Age Specific Incidence Rates of skin cancer in Sri Lanka, 2021	52
Figure 36:	Age Standardized Incidence Rates of Skin cancer in Sri Lanka, 2005 - 2021	52
Figure 37:	Age Specific Incidence Rates of Breast cancer, 2021	55
Figure 38:	Age Standardized Incidence Rates of Breast cancer in Sri Lanka, 2005-2021	55
Figure 39:	Age Specific Incidence Rates of Cervical cancer in Sri Lanka, 2021	57
Figure 40:	Age Standardized Incidence Rates of Cervical cancer in Sri Lanka, 2005-2021	57
Figure 41:	Age Specific Incidence Rates of Uterine cancer in Sri Lanka, 2021	60
Figure 42:	Age Standardized Incidence Rates of Uterine cancer in Sri Lanka, 2006-2021	60
Figure 43:	Age Specific Incidence Rates of Ovarian cancer in Sri Lanka, 2021	63
Figure 44:	Age Standardized Incidence Rates of Ovarian cancer in Sri Lanka, 2005-2021	63
Figure 45:	Age Specific Incidence Rates of Prostate cancer in Sri Lanka, 2021	65
Figure 46:	Age Standardized Incidence Rates of Prostate cancer, 2005- 2021	65
Figure 47:	Age Specific Incidence Rates of Urinary bladder cancer in Sri Lanka, 2021	67
Figure 48:	Age Standardized Incidence Rates of Urinary bladder cancer in Sri Lanka, 2005-2021	67
Figure 49:	Age Specific Incidence Rates of Thyroid cancer in Sri Lanka, 2021	69
Figure 50:	Age Standardized Incidence Rates of Thyroid cancer in Sri Lanka, 2005-2021	69
Figure 51:	Age Specific Incidence Rates of Lymphoma in Sri Lanka, 2021	72
Figure 52:	Age Standardized Incidence Rate of Lymphoma in Sri Lanka, 2011-2021	72
Figure 53:	Age Specific Incidence Rates of Leukaemia in Sri Lanka, 2021	75
Figure 54:	Age Standardized Incidence Rates of Leukemia in Sri Lanka, 2011 – 2021	75
Figure 55:	Clinical staging at the point of diagnosis of breast cancer	76

List of Figures

Figure No	Description	Page No
Figure 56:	Clinical staging at the point of diagnosis of cervical cancer	76
Figure 57:	Clinical staging at the point of diagnosis of lip, tongue and mouth cancer	76
Figure 58:	Basis of diagnosis of cancer in Sri Lanka, 2021	77
Figure 59:	Percentage of newly detected cancer patients who received different types of treatment In Sri Lanka, 2021	78
Figure 60:	Cancer Incidence data by districts among males in Sri Lanka, 2021	96
Figure 61:	Cancer Incidence data by districts among females in Sri Lanka, 2021	101
Figure 62:	Crude Death Rate due to cancers in Sri Lanka Based on Vital Registration System 2001 -2019	107
Figure 63:	Age Standardized death Rates due to cancer based on Vital Registration system 2001 -2019	107
Figure 64:	Proportion of leading cancer deaths among males based on deaths reported to Vital Registration system of Sri Lanka, 2019	109
Figure 65:	Proportion of leading cancer deaths among females based on deaths reported to Vital Registration system of Sri Lanka, 2019	109
Figure 66:	Age Standardized Mortality Rates due to cancers of Trachea, bronchus, and lung	110
Figure 67:	Age Standardized Mortality Rates due to cancers of Lip, oral cavity, and pharynx	110
Figure 68:	Age Standardized Mortality Rates due to cancers of Breast	110
Figure 69:	Age Standardized Mortality Rates due to cancers of Liver and intrahepatic bile ducts	110
Figure 70:	Age Standardized Mortality Rates due to Cancers of Oesophagus	110
Figure 71:	Age Standardized Mortality Rates due to Cancers of Cervix uteri	110
Figure 72:	Age Standardized Mortality Rates due to cancers of Colon, rectum, and anus	111
Figure 73:	Age Standardized Mortality Rates of death due to cancers of Prostate	111
Figure 74:	Breast cancer deaths in each year (2010 to 2019) by age groups	112
Figure 75:	Oral cancer deaths in each year (2010 to 2019) by age groups	112
Figure 76:	Cervical cancer deaths in each year (2010 to 2019) by age groups	112

Message from the Director General of Health Services



It is with great pleasure I issue this message to the 23rd publication of 'Cancer Incidence and Mortality Data Sri Lanka – 2021' published by the National Cancer Control Programme, Ministry of Health.

Publication of cancer incidence and mortality data is essentially needed to plan, implement and monitor prevention and control of cancer (malignancy) at the national level and sub national level. Therefore, timely availability of this information is essential.

The relevant information needs to be accessible to policy makers, administrators of health care services, clinicians, public health professionals, academia, researchers, media professionals and general public.

I take this opportunity to thank all stakeholders involved in cancer surveillance at central level and regional level. Further contributions are needed to improve the data quality and timeliness in future.

Dr. Asela Gunawardena

Director General of Health Services

Message from the Deputy Director General (Non- Communicable Diseases)



I am happy to issue this message to the 23rd publication of 'Cancer Incidence & Mortality Data Sri Lanka 2021'. This publication is the most comprehensive detailed description of latest burden of cancer in Sri Lanka.

Hope the data consumers at the national and regional level refer this data for planning, implementing, and monitoring the cancer control activities in the country. It is a good practice to disseminate the electronic version of this publication for wider usage.

The dedicated contributions at the point of diagnosis (histopathology / haematology/ oral pathology laboratories), point of cancer treatment (cancer treatment centres, OMF Units etc) and point of death (divisional death registrars of Colombo district) are highly appreciated. The contributions of central level staff at the National Cancer Control Programme are also appreciated. In addition, contributions of WHO country office, IARC Regional Hub for Cancer Registration, Mumbai, India are acknowledged.

Dr. Champika Wickramasinghe

MBBS, MSc, MD (Community Medicine)

Deputy Director General (Non-Communicable Diseases)

Foreword



Surveillance of cancers is one of the key strategies of cancer control in any country. On behalf of Ministry of Health, National Cancer Control Programme (NCCP) coordinates surveillance of cancers in coordination with government and private sector hospitals including cancer treatment centres, pathology laboratories, Oro Maxillo Facial Units and Medical Statistics Units. Since mortality is one of the main outcome measures of cancer control, the National Cancer Control Programme closely works with Vital Registration System in the country including Registrar General Department to obtain timely information on deaths due to cancers. As a main deliverable of cancer surveillance of the country, 'Cancer incidence & Mortality Data Sri Lanka' is published regularly describing the latest cancer burden in the country. This is the 23rd publication.

In addition, WHO country office continuously provides technical assistance to further strengthen cancer registration in Sri Lanka. Continuous technical assistance is provided by the WHO IARC Regional Hub for Cancer Registration in Mumbai India. Technical support is also obtained through the Vital Strategies Inc to strengthen Population Based Cancer Registries initiatives in selected district.

I take this opportunity to thank the all categories of health and non-health staff for their tireless contribution to the cancer registration process enabling NCCP to generate this publication. NCCP would like to receive observations from all those who refer this publication to further improve this publication.

Dr. Eshani Fernando

MBBS, MSc, MD (Community Dentistry)

Director, National Cancer Control Programme

Contributors

Data entry to 'Can Reg 5' at hospital level

Medical Officers / Nursing Officers / Development Officers at the cancer treatment centres, Pre interns

Dental surgeons / Nursing Officers / Development Officers at the OMF Units

Pathology laboratory surveillance at hospital level

Consultants / Medical Officers /Dental Surgeons / Medical Laboratory Technologists/ Development Officers / Health Management Assistants at Histopathology / Haematology/ Oral Pathology laboratories

Data Entry & Duplicate checking at the centre

Mrs. Nimesha Prasadi

Mrs. Nayomi Weerasingha

Data Coding, Duplicate Checking, Data Verification

Dr. K. G. Nirmala Jayanthi

Dr. Chathurika Jayamani

Dr. Nirma Alapitaarachchi

Dr. Chulaka Jayaweera

Dr. Gayani Kalhari

Mrs. Chamila Peiris

Ms. Sachini Sashikala

Dr. Lanka Kumari

Coordination of Oral Cancer Surveillance including duplicate checking at the main database

Dr. Udaya Usgodarachchi

Dr. J.K.Anuraddha Indiwaree

Dr. Asanga Abeynayaka

Dr. Tharani Rajendra

Dr. Priyanka Rajapaksha

Statistical analysis and report writing

Dr. K.G. Nirmala Jayanthi

Dr. Nirma Alpitiarachchi

Dr. Gayani Kalhari

Dr. Chulaka Jayaweera

Dr. Janaka C. Godevithana

Dr. Suraj Perera

Cover page & Infographics

Ms. Ambika Sundarasan

GIS Maps

Dr. Janaka C. Godevithana

Support staff

Mr. Saman Kumara Mahalekam

Mr. Amila Bandara

Mr. Nalinda Sanjeewa

Mrs. Thushari Dammika

Mr. Roshan Madumal

Mr. Ajith Wanaguru

Mrs. Deepa Pathmanjali

Mr. Saman Aururuddha

Co-Investigator

Dr. Suraj Perera

Principal Investigator

Dr. Eshani Fernando

Acknowledgements

National Advisory Committee on Prevention & Control of Cancers

Technical Advisory Committee on Cancer Registration & Research

World Health Organization - Country Office, Sri Lanka

All government cancer treatment centers

Oral and Maxillo - Facial surgery units

All pathology laboratories

Private hospitals

Sri Lanka College of Oncologists

Ceylon College of Pathologists

Sri Lanka College of Haematologists

Association of Oral Pathology & Oral Medicine

College of Oral Medicine & Oral Pathology

Executive Summary

'Cancer Incidence and Mortality Data, Sri Lanka – 2021' is the 23rd volume of the publication on cancer surveillance data, Sri Lanka. This publication is based on the newly reported cancers in the year 2021. The newly detected cancers in year 2021 at the point of diagnosis (histopathology, haematology, oral pathology laboratories) and at the point of treatment (cancer treatment centers, Oral and Maxillo Facial surgery units) throughout the country were considered for this publication. All the data were entered into the 'CanReg 5' central data base. Quality checks were conducted and duplicate entries were eliminated. Analysis was done using 'CanReg 5' and SPSS software. For cancer mortality data, since cause specific death data for year 2021 is not yet published by the Registrar General's Department, cause specific data of year 2019 and hospital mortality data received from Medical Statistics Unit, Ministry of Health were analyzed.

In the year 2021, a total number of 37,753 patients were newly diagnosed with cancer, giving crude incidence rate (CR) of 170.4 per 100,000 population. Crude incidence rate of males and females were 163.9/100,000 and 176.5/100,000 respectively. The highest 5-year age specific incidence rates were reported among males and females of 70 - 74 year age group (Males 1323.7/100 000 and females 924.5 /100 000). When age standardized incidence rates (ASR) were considered, the overall ASR was 151.3/100 000 and the ASR for males and females were 155.1/100 000 and 150.4/100 000.

Lip, tongue and mouth (n=2687, CR= 25.0/100 000), Trachea, bronchus and lung cancers (n=1540, CR 14.4/100 000), Colon and rectum (n= 1522, CR= 14.2/100 000), Oesophagus (n=1364, CR = 12.7/100 000) and Prostate (n= 1286, CR= 12.0/100 000) were the highest incident cancers among males in year 2021 too. Out of all male cancers, 15 % were lip, tongue and mouth cancers.

Breast (n= 5485, CR= 48.0/100 000), Thyroid (n=2043, CR= 17.9/100 000), Colon and Rectum cancers (n= 1596, CR= 14.0/100 000), Ovary (n= 1308, CR= 11.4/100 000) and Cervix uteri (n=1238, CR=10.8/100 000) were the highest incident cancers among females. Out of all female cancers 27% were breast cancers.


Cumulative rate of developing cancer between the age group of 0 -74 years males is 19.6% and females is 17.9%. It means that among 1 in 5.1 males and 1 in 5.6 females have risk of developing cancer during their life time.

Staging information was available for 35% breast cancers, 14% cervical cancers and 28% lip tongue and mouth cancers. Among those with staging information 37% breast cancers, 47% cervical cancers and 63% lip, tongue and mouth cancers were diagnosed at the advanced stages (Stage III and IV).


There were 1032 cases of childhood and adolescent cancers (age between 0 -19 Years) and 33.0% were leukaemias. Out of all cancers 96.7 % were diagnosed microscopically and histopathology details were available for 90.1% cancers. Highest number of cancers were reported from Colombo (n=3686, CR=143.7), Gampaha (n=2536, CR=103.8), Kurunegala (n=1791, CR=102.8), Kandy (n=1632, CR= 108.7) and Rathnapura (n=1446, CR=121.5) districts.

A total of 5,112 deaths were occurred due to cancers at government hospital settings in year 2021 according to the information received from Medical Statistics Unit of Ministry of Health.


Cancer Incidence Sri Lanka 2021




About **103** new patients are diagnosed per day




Leading Cancer Sites by Sex in Sri Lanka 2021





Crude Incidence rate of five common male cancers 2005 -2021





Crude Incidence rate of five common female cancers 2005 -2021

Childhood Cancer Sri Lanka 2021



578 Boys | 454 Girls

1032 Children (0-19) were diagnosed with cancer in 2021



Number of cases of Childhood cancers 2005-2021

Cancer Incidence and Mortality Data Sri Lanka - 2021

1. Introduction

Cancer surveillance (Cancer registration) is a process of systematic, continuous collection, storage, analysis, interpretation, and dissemination of epidemiological information on cancers occurring in a country or a specific geographic area. Information generated from the cancer registration is essential for planning, implementation, monitoring, and evaluation of cancer control activities of the country.

The National Cancer Control Programme (NCCP) of the Ministry of Health coordinates the National Cancer Registry Programme in Sri Lanka with the active participation of several stakeholders for cancer registration including cancer treatment centres, pathology laboratories, Oral and Maxillo Facial (OMF) surgery units, Medical Statistics Unit, professional colleges, WHO country office etc. In addition, Registrar Generals' Department and Department of Census and Statistics actively contribute to cancer mortality data.

The process of surveillance of cancers is technically guided by National Advisory Committee on Prevention & Control of Cancers and the Technical Advisory Committee on Cancer Registration & Research. Also, the technical support for cancer registration was received through the International Agency for Research on Cancer (IARC) of World Health Organization (WHO) and WHO IARC Regional Hub for Cancer Registration, Mumbai India. In addition, technical guidance is received from Department of Epidemiology, Biostatistics and Cancer Registry, WIA Cancer Institute, Chennai India.

The information based on surveillance of cancers is published as 'Cancer Incidence & Mortality Data Sri Lanka'. To date 22 volumes have been published. The current publication is the 23rd volume of 'Cancer Incidence & Mortality Data Sri Lanka' 2021.

2. Methodology

Process of cancer registration




Figure 1:Flow diagram of the process of cancer registration in Sri Lanka

2.1 Collection of cancer incidence and mortality data

Cancer incidence data were collected from cancer treatment centres, pathology laboratories and Oral & Maxillo-Facial (OMF) Surgery units throughout the country.

2.1.1 Newly registered cancer patients at the cancer treatment centres

The patient details and tumour details of newly registered cancer patients were extracted from 25 government cancer treatment centres (table 1). Relevant data were extracted from cancer patients' clinic records using 'National Cancer Surveillance Form – H 1256'. Medical officers, nursing officers or development officers attached to the cancer treatment centres actively involved in documenting or extracting relevant cancer incidence data. In some centres trained pre-intern medical graduates who were temporarily recruited through WHO Biennium funds extracted from the cancer patients' clinic records. The extracted data were entered into the 'CanReg 5', data base at the cancer treatment centre.

Table 1 : Distribution of government cancer treatment centres in year 2021

Category of hospital	Name of the hospital
National Hospitals	Apeksha Hospital - Maharagama (National Cancer Institute), National Hospital Kandy
Teaching Hospitals	Colombo North Teaching Hospital, Karapitiya, Anuradhapura, Batticaloa, Rathnapura, Kurunegala, Badulla, Kalutara
District General Hospitals	Gampaha, Avissawella, Nuwaraeliya, Matale, Matara, Hambantota, Polonnaruwa, Vavuniya, Chilaw, Trincomalee, Ampara, Kegalle, Moneragala, Embilipitiya
Base Hospital	Tellippalai (Jaffna)

After the quality assessment, the excel sheet was arranged according to the required format for uploading to CanReg 5. Excel sheets were uploaded to a standalone CanReg 5 data base. From the stand alone CanReg 5 data base, Patient, Tumour & Source files were generated separately in .tsv format. Patient, tumour, source files were uploaded to 'Rupantharan' software. Through the 'Rupantharan' Software cancer incidence data were uploaded to the central cancer registry database.

2.1.2 Newly detected cancers at the pathology laboratories

The information on newly detected cancers at the pathology laboratories were received monthly through the 'Cancer Return Form - 1' (H-1290). A total of 63 Histopathology laboratories (20,344 diagnosed patients), 37 Haematology laboratories (863 diagnosed patients) and 3 oral pathology laboratories (731 diagnosed patients) have passively sent relevant data for the year 2021 (table ii).

Table 2: Distribution of pathology laboratories which sent details of newly diagnosed cancer patients in year 2021

Category of hospital	Type of Pathology laboratory		
	Histopathology	Haematology	Oral Pathology
National Hospital	National Hospital of Sri Lanka, National Hospital of Kandy, National Eye Hospital, National Hospital for Respiratory Diseases-Welisara	National Hospital of Kandy	National Dental Hospital
Teaching Hospitals	De Soysa Hospital for Women, Castle Hospital for Women, Lady Ridgeway Hospital, Colombo South, Colombo North, Sri Jayawardenapura, Karapitiya, Rathnapura, Anuradhapura, Peradeniya, SBCH, Batticaloa, Jaffna, Kuliyapitiya, Kotalawala Defence University Hospital, Kalutara, Badulla, Kurunegala	Lady Ridgeway Hospital, Colombo South, Colombo North, Karapitiya, Sri Jayawardenapura, Rathnapura, SBCH, Kurunegala, Kuliyapitiya, Anuradhapura, Peradeniya, Batticaloa, Kotalawala Defence University Hospital, Badulla	Karapitiya
District General Hospitals	Avissawella, Gampaha, Negombo, Matara, Hambanthota, Kegalle, Chilaw, Polonnaruwa, Nawalapitiya, Matale, Ampara, Trincomalee Vavuniya, Kilinochchi, Mannar, Mullativu	Gampaha, Negombo, Kegalle, Nawalapitiya Monaragala, Vavuniya, Avisawella, Hambanthota, Embilipitiya, Nuwaraeliya, Matale, Mannar, Polonnaruwa	
Base Hospital	Homagama, Mulleriyawa, Wathupitiwala, Balapitiya, Elpitiya, Tangalle, Kamburupitiya, Embilipitiya, Balangoda, Puttalam, Gampola, Dambulla, Diyathalawa, Mahiyanganaya, Karawanella, Thambuttegama, Ashroff Memorial Hoospital – Kalmunai, Horana	Wathupitiwala, Panadura, , Balapitiya, Elpitiya, Tangalle, Puttalam, Horana	
University Units	Faculty of Medicine – Colombo, Ruhuna, Faculty of Medicine– University of Sri Jayawardanapura, Ragama	Sri Jayawardanapura	Faculty of Dental Sciences– Peradeniya
Private Sector	Delmons Hospital – Colombo, Kings Hospital - Colombo, Asiri Hospital - Colombo, Asiri Hospital - Kandy		

Most of the pathology laboratories send the data as a paper-based reports. The reported cancers were coded by the cancer registry staff of NCCP and entered to the central CanReg database at the NCCP. According to the instructions of International Classification of Disease for Oncology 3rd edition (ICD-O 3), cancer incidence data were coded according to the site (Topography) and the histology (Morphology) of cancer.

Some returns were received as an Excel sheet and NCCP staff coded and uploaded into the main CanReg 5 database via 'Rupantharan' software.

2.1.3 Newly diagnosed cancers at the Oral & Maxillo - Facial (OMF) Surgery Units

In year 2022/ 2023 through Primary Health Care System Project funds (PHCSP) CanReg 5 data base was introduced to each OMF Unit. Staff was also trained on CanReg 5 data base handling. From year 2022, details of newly registered oral cancer patients at the Oral & Maxillo-Facial (OMF) surgery units were received through Can Reg 5 database in 28 centres. Teaching Hospital Kurunegala provided newly registered oral cancer data through the Annual Notification Form of Oral Cancer (H -1293). Therefore, finally a total of 29 OMF units (1624 patients) have sent relevant data for year 2021(table 3).

Table 3 : Distribution of OMF Units which sent details of newly diagnosed cancer patients in year 2021

Category of hospital	Name of the hospital
National Hospitals	Kandy, Dental Institute -Colombo
Teaching Hospitals	Colombo South, Colombo North, Karapitiya, Rathnaura, Anuradhapura, Jaffna, Kuliypitiya, Kurunegala, Batticaloa, Badulla
District General Hospitals	Ampara, Gampaha, Kalutara, Chilaw, Polonnaruwa, Hambantota, Matara, Nuwara Eliya, Trincomalee, Embilipitiya, Kegalle, Negombo, Vavuniya, Avissawella, Matale
Base Hospital	Panadura
University Units	Faculty of Dental Sciences, Peradeniya

2.1.4 Cancer mortality data reported by the Divisional Death Registrars of the Colombo District

In the district of Colombo, cancer mortality data are collected. Details of all cancer related deaths registered by the Divisional Death Registrars of the Colombo district were received through the Cancer Return Form – 3. A total of 40 divisional death registrars have sent relevant details for the year 2021.

The newly reported cancer mortality data as paper-based reports. Reported cancers were coded by the cancer registry staff of NCCP and entered into the central CanReg database at the NCCP.

2.2 Duplicate checking & verification of data

Since National Cancer Registry - Sri Lanka extracts data on cancer incidence from multiple sources, occurrence of duplicates is inevitable. Therefore, while entering and confirming the data to the CanReg5 data base, duplicate checking was conducted using 'Person search' option of the CanReg 5. In addition to the duplicate checking done through CanReg 5, further duplicates were identified and removed using MS Excel and Linkpro software.

Mismatches according to.

- Age/Incidence and birthdates
- Age /Site /Histology
- Site /Histology
- Sex/Site
- Sex/Histology
- Behaviour /Site
- Behaviour / Histology
- Grade /Histology Basis of Diagnosis /Histology

To ensure reliability of data, the mismatching data was cross checked with original data source and corrected. Data sources up to the patient clinic files were rechecked in instances where mismatches were noted by the cancer registry staff of the NCCP. After identifying errors or misclassifications, necessary corrections were done before finalizing the data for analysis.

2.5 Analysis of registry data & dissemination of Information

Data analysis was conducted using CanReg 5 software package, SPSS and MS Excel. The standard cancer registry tables described at the CI 5 were generated through CanReg 5 database. The frequency distribution of cancers and their percentages and age-specific incidence rates were calculated using MS Excel and SPSS software version 22. The final report will be disseminated as 'Cancer Incidence & Mortality Data Sri Lanka 2021'.

Population estimates used for incidence rate calculations are given in table 4 & 5.

Table 4 : Estimated mid-year population by five-year age groups in Sri Lanka 2021

Age group	Male	Female	Total
0-4	959,047	943,139	1,902,186
5-9	961,616	943,742	1,905,358
10-14	903,747	884,168	1,787,915
15-19	893,565	898,640	1,792,204
20-24	807,779	860,705	1,668,484
25-29	809,192	881,287	1,690,480
30-34	867,043	916,991	1,784,033
35-39	746,224	786,500	1,532,725
40-44	719,423	758,502	1,477,925
45-49	672,368	726,128	1,398,496
50-54	632,127	693,685	1,325,811
55-59	544,418	612,022	1,156,440
60 - 64	462,046	534,540	996,586
65 - 69	307,815	378,932	686,747
70 - 74	197,252	249,871	447,124
75+	243,478	359,756	603,234
Total	10,727,141	11,428,607	22,155,748

Source- Department of Census and Statistics

Table 5 : Estimated mid-year population by district in Sri Lanka 2021

Disctric	Male	Female	Total
Colombo	1,216,608	1,262,910	2,479,518
Gampaha	1,183,611	1,258,901	2,442,512
Kalutara	627,118	668,885	1,296,003
Kandy	715,783	785,419	1,501,202
Matale	255,565	274,396	529,961
Nuwara Eliya	373,078	407,005	780,083
Galle	549,623	596,544	1,146,167
Matara	417,893	454,593	872,486
Hambantota	332,166	343,922	676,088
Jaffna	294,182	332,311	626,493
Mannar	57,281	56,668	113,949
Vavuniya	95,426	98,451	193,877
Mulativu	49,118	49,295	98,413
Kilinochchi	65,471	67,753	133,224
Batticaloa	281,045	309,315	590,360
Ampara	364,051	388,021	752,072
Trincomalee	217,799	223,139	440,938
Kurunagala	836,878	905,860	1,742,738
Puttalam	410,602	437,815	848,417
Anuradhapura	465,684	488,270	953,954
Pollonnaruwa	221,432	226,426	447,858
Badulla	430,404	465,004	895,408
Moneragala	251,131	254,181	505,312
Rathnapura	586,714	603,345	1,190,059
Kegalle	428,478	470,178	898,656
Total	10,727,141	11,428,607	22,155,748

Source- Department of Census and Statistics

Cancer Incidence Data of Sri Lanka - 2021




Figure 2: Population pyramid of Sri Lanka in 2021 by 5- year age groups

Table 6 : Cancer Incidence by sex in Sri Lanka, 2005 - 2021

Year	Sex	No.	%	CR	ASR
2005	Male	6,058	45.3	62.3	68.1
	Female	7,313	54.7	73.4	73.4
	Total	13,372		67.9	70.6
2006	Male	6,205	44.1	62.7	69.2
	Female	7,875	55.9	79.0	79.5
	Total	14,080		70.9	74.2
2007	Male	6,356	46.6	63.8	70.9
	Female	7,279	53.4	72.2	72.8
	Total	13,635		68.0	71.6
2008	Male	7,695	46.6	76.5	85.5
	Female	8,816	53.4	86.6	88.0
	Total	16,511		81.6	86.4
2009	Male	7,858	46.5	77.4	86.4
	Female	9,030	53.5	87.7	89.1
	Total	16,888		82.6	87.5
2010	Male	7,993	47.1	78	87.4
	Female	8,970	52.9	86.2	87.7
	Total	16,963		82.1	87.3
2011	Male	8,370	47.8	80.6	90.4
	Female	9,112	52.1	86.7	88.7
	Total	17,482		83.7	89.2
2012	Male	11,363	49.1	115.3	107.8
	Female	11,773	50.9	112.1	95.5
	Total	23,136		113.6	100.1
2013	Male	11,364	48.2	114	106.3
	Female	12,167	51.8	114.6	97.4
	Total	23,531		114.3	100.7
2014	Male	12,021	47.6	119.5	112
	Female	13,250	52.4	123.6	105.3
	Total	25,271		121.6	107.3
2015	Male	13,921	48.1	137.1	128.6
	Female	15,046	51.9	139.1	118.8
	Total	28,967		138.1	122
2016	Male	16,533	48.4	161.1	151.2
	Female	17,646	51.6	161.3	137.4
	Total	34,179		161.2	142
2017	Male	15,458	48.1	148.9	140.2
	Female	16,712	51.9	151.1	128.8
	Total	32,170		150	132.7
2018	Male	14,917	48.3	142.2	133.6
	Female	15,936	51.7	142.6	121.1
	Total	30,853		142.4	125.8
2019	Male	14855	46.6	140.6	132.6
	Female	16994	53.4	151.1	128.8
	Total	31,849		146	128.9
2020	Male	17,451	46.4	164.4	155.3
	Female	20,197	53.6	178.6	152.2
	Total	37,648		171.8	152.3
2021	Male	17,582	46.6	163.9	155.1
	Female	20,171	53.4	176.5	150.4
	Total	37,753		170.4	151.3




Figure 3: Crude Cancer Incidence Rates of Sri Lanka, 2005-2021



Figure 4: Age Standardized Cancer Incidence Rates of Sri Lanka, 2005-2021




Figure 5: Cancer Incidence Rates of Sri Lanka in 2021

Table 7: Cancer Incidence by 5 – year age groups and sex in Sri Lanka, 2021

Age group	Male			Female			Total		
	Cases	Population	Age sp. Incidence rate	Cases	Population	Age sp. Incidence rate	Cases	Population	Age sp. Incidence rate
Unknown	29			18			47		
00-04	205	959,047	21.4	138	943139	14.6	343	1902186	18.0
05-09	108	961,616	11.2	83	943742	8.8	191	1905358	10.0
10-14	113	903,747	12.5	98	884168	11.1	211	1787915	11.8
15-19	152	893,565	17.0	135	898640	15.0	287	1792204	16.0
20-24	150	807,779	18.6	240	860705	27.9	390	1668484	23.4
25-29	193	809,192	23.9	405	881287	46.0	598	1690480	35.4
30-34	234	867,043	27.0	479	916991	52.2	713	1784033	40.0
35-39	386	746,224	51.7	936	786500	119.0	1322	1532725	86.3
40-44	595	719,423	82.7	1359	758502	179.2	1954	1477925	132.2
45-49	893	672,368	132.8	1736	726128	239.1	2629	1398496	188.0
50-54	1618	632,127	256.0	2136	693685	307.9	3754	1325811	283.1
55-59	2201	544,418	404.3	2442	612022	399.0	4643	1156440	401.5
60-64	2994	462,046	648.0	2866	534540	536.2	5860	996586	588.0
65-69	2720	307,815	883.6	2596	378932	685.1	5316	686747	774.1
70-74	2611	197,252	1323.7	2310	249871	924.5	4921	447124	1100.6
75+	2380	243,478	977.5	2194	359756	609.9	4574	603234	758.2
Total	17582	10727141	163.9	20171	11428607	176.5	37753	22155748	170.4




Figure 6: Age Specific Cancer Rates Sri Lanka, 2021

Table 8: Leading cancer site by sex in Sri Lanka, 2021

Male					Female				
ICD code	Site	No	CR	ASR	ICD code	Site	No	CR	ASR
C00-C06	Lip, tongue, and mouth	2687	25.0	23.1	C50	Breast	5485	48.0	40.5
C33-C34	Trachea, bronchus, and lung	1540	14.4	13.7	C73	Thyroid	2043	17.9	15.9
C18-C20	Colon and rectum	1522	14.2	13.3	C18-C20	Colon and rectum	1596	14.0	11.6
C15	Oesophagus	1364	12.7	11.9	C56	Ovary	1308	11.4	9.9
C61	Prostate	1286	12.0	11.6	C53	Cervix uteri	1238	10.8	9.1
C09-C14	Pharynx	980	9.1	8.5	C54-C55	Uterus	1228	10.7	9.0
C81-C85,96	Lymphoma	842	7.8	7.5	C15	Oesophagus	965	8.4	6.8
C67	Bladder	731	6.8	6.5	C00-C06	Lip, tongue, and mouth	674	5.9	4.8
C91-C95	Leukaemia	602	5.6	5.7	C81-C85, C96	Lymphoma	619	5.4	4.8
C32	Larynx	586	5.5	5.1	C33-C34	Trachea, bronchus and lung	551	4.8	4.0
	All sites	17582	163.9	155.1		All sites	20171	176.5	150.4




Figure 7: Proportion of leading cancers in males in Sri Lanka, 2021




Figure 8: Proportion of leading cancers in females in Sri Lanka, 2021

Crude incidence rates of leading cancer in Sri Lanka, 2021




Figure 9: Crude incidence rates of leading cancer in males in Sri Lanka, 2021




Figure 10: Crude incidence rates of leading cancer in females in Sri Lanka, 2021

Leading cancers of Sri Lanka according to age group in 2021

00-14 year age group




Figure 11: Leading cancer by 00 – 14 age group among males in Sri Lanka, 2021




Figure 12: Leading cancer by 00 – 14 age group among females in Sri Lanka, 2021

15–34 year age group




Figure 13: Leading cancer by 15 -34 age group among males in Sri Lanka, 2021




Figure 14: Leading cancer by 15 -34 age group among females in Sri Lanka, 2021

35–49 year age group




Figure 15: Leading cancer by 35–49 age group among males in Sri Lanka, 2021




Figure 16: Leading cancer by 35–49 age group among females in Sri Lanka, 2021

50 – 64 year age group




Figure 17: Leading cancer by 50 – 64 age group among males in Sri Lanka, 2021




Figure 18: Leading cancer by 50 – 64 age group among females in Sri Lanka, 2021

65 years and above age group




Figure 19: Leading cancer by 65 years and above age group among males in Sri Lanka, 2021




Figure 20: Leading cancer by 65 years and above age group among females in Sri Lanka, 2021

Table 9: Number of cancers by 5-year age groups and ICD 10 site among males in Sri Lanka, 2021

ICD 10 Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Unknown	Total
C00 Lip	0	0	0	0	1	0	2	4	3	8	12	15	15	13	15	15	0	103
C01 Base of tongue	0	0	0	0	0	0	1	1	5	15	26	39	28	22	29	25	1	192
C02 Other and unspecified parts of the tongue	0	0	0	1	2	2	7	22	48	75	121	114	142	87	86	71	1	779
C03 Gum	0	0	0	0	0	0	0	3	4	7	9	17	22	17	17	17	0	113
C04 Floor of mouth	0	0	0	0	0	0	1	4	8	8	20	49	33	36	27	19	0	205
C05 Palate	0	0	0	0	1	1	3	5	12	17	51	36	44	40	27	39	2	278
C06 Other and unspecified	0	0	0	0	0	1	10	32	31	78	114	143	180	147	139	141	1	1017
C07 Parotid gland	0	0	1	0	3	1	2	6	1	10	7	11	8	11	12	9	0	82
C08 Other and unspecified salivary gland	0	0	0	0	0	0	1	0	3	1	3	6	12	4	7	8	0	45
C09 Tonsil	0	0	1	0	0	0	0	0	3	11	27	46	47	35	38	17	2	227
C10 Oropharynx	0	0	0	0	0	0	0	0	4	15	29	38	49	41	30	17	0	223
C11 Nasopharynx	1	0	1	2	1	0	0	0	0	5	8	5	5	5	2	4	0	39
C12 Piriform sinuses	0	0	0	0	0	1	2	1	4	1	21	45	42	41	41	33	0	232
C13 Hypopharynx	0	0	0	0	0	0	2	0	1	2	7	19	20	21	20	15	0	107
C14 Other and ill-defined sites in the lip, oral cavity and Pharynx	0	0	0	0	1	0	0	0	3	7	16	28	33	30	11	21	2	152
C15 Oesophagus	0	0	0	0	1	1	7	4	25	57	132	203	307	219	215	188	5	1364
C16 Stomach	0	0	0	0	1	2	5	3	12	20	26	69	78	99	54	51	0	420
C17 Small intestine	0	0	0	0	1	0	0	1	4	6	5	16	12	7	12	12	1	77
C18 Colon	0	1	0	1	4	4	8	15	30	37	61	71	107	99	105	80	1	624
C19 Rectosigmoid junction	0	0	0	0	0	0	3	4	4	7	8	19	21	15	17	15	0	113
C20 Rectum	0	0	0	0	4	3	5	15	31	49	70	93	137	140	107	130	1	785
C21 Anus	0	0	0	0	0	2	3	2	3	4	10	10	18	12	8	18	1	91
C22 Liver and intrahepatic bile ducts	7	0	0	1	2	1	3	2	8	16	26	68	88	97	76	67	0	462
C23 Gallbladder	0	0	0	0	0	0	0	0	2	4	3	9	7	11	6	7	0	49
C24 Other and unspecified parts of biliary tract	0	0	0	0	0	0	1	0	2	4	8	11	13	8	12	7	0	66
C25 Pancreas	1	0	1	0	0	2	1	0	7	11	14	14	23	19	18	21	0	132
C26 Other and ill-defined digestive organs	0	0	0	0	1	0	0	1	1	4	1	6	5	8	3	3	0	33
C30 Nasal cavity and middle ear	1	0	0	1	2	0	1	2	1	3	2	5	7	8	8	7	0	48
C31 Accessory sinus	0	0	0	0	0	0	0	2	2	2	4	3	8	8	3	2	0	34
C32 Larynx	0	0	0	0	0	1	1	4	7	17	74	90	122	116	83	71	0	586
C33 Trachea																		
C34 Bronchus and lung	0	0	0	0	7	2	7	20	22	40	107	209	329	339	268	188	2	1540
C37 Thymus	0	0	0	1	1	1	2	1	2	2	4	0	4	0	3	1	0	22
C38 Heart, mediastinum and pleura	1	0	1	5	0	0	1	0	1	1	1	2	5	8	5	3	0	34
C39 Other and ill-defined sites in the respiratory system and intrathoracic organs	0	0	0	0	0	0	0	0	0	0	0	0	1	2	0	1	0	4
C40 Bones and cartilage of limbs	1	5	12	21	8	4	3	5	0	2	5	6	6	1	3	3	0	85
C41 Bone and articular cartilage of other and unspecified sites	3	2	5	7	4	5	0	7	1	1	5	6	4	4	3	3	0	60
C43 Melanoma of skin	0	0	0	1	0	0	2	0	0	1	7	14	8	8	15	7	0	63
C44 Other malignant neoplasms of skin	0	1	1	0	3	4	3	9	14	20	33	33	57	48	39	61	0	326
C45 Mesothelioma	0	0	0	0	0	0	2	2	0	0	2	3	0	1	1	2	0	13
C47 Peripheral nervous and autonomic nerves system	1	1	1	0	1	0	1	0	1	1	0	1	0	0	1	0	0	9

Table 09 continued...

ICD 10 Site	00-04	05-09	10-14	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Unknown	Total
C48 Retroperitoneum and Peritoneum	0	0	0	0	1	0	0	1	1	0	1	5	6	5	3	1	0	24
C49 Other connective and soft tissue	6	1	9	4	3	5	6	11	12	7	18	25	23	20	6	4	0	160
C50 Breast	0	0	0	0	0	1	3	3	7	17	14	15	13	13	20	18	0	124
C60 Penis	0	0	0	0	0	0	2	0	4	7	11	8	20	21	13	25	0	111
C61 Prostate	0	0	0	0	0	0	0	1	3	4	35	67	178	229	363	405	1	1286
C62 Testis	6	1	3	10	8	15	10	6	2	1	4	2	1	3	3	6	0	81
C63 Other and unspecified male genital organs	0	0	0	0	0	0	1	0	1	0	2	1	1	0	0	2	0	8
C64 Kidney, except renal pelvis	19	6	0	0	2	1	6	7	10	29	35	39	67	49	42	32	2	346
C65 Renal pelvis	0	0	0	0	0	0	0	0	1	0	2	0	10	4	1	5	0	23
C66 Ureter	0	0	0	0	0	0	0	0	0	0	0	0	1	3	1	0	0	5
C67 Bladder	0	1	0	2	1	4	1	9	8	9	46	67	130	132	155	163	3	731
C68 Other and unspecified urinary organs	0	0	0	0	0	0	0	0	0	0	0	0	2	1	2	1	0	6
C69 Eye and adnexa	17	0	0	0	1	1	0	2	0	2	2	1	6	2	4	1	0	39
C70 Meninges	0	0	1	0	1	1	1	1	3	3	3	2	4	0	1	0	0	21
C71 Brain	17	10	13	10	5	10	10	20	30	28	28	39	28	19	21	8	0	296
C72 Spinal cord, cranial nerves and other parts of central nervous system	3	0	0	0	0	2	2	0	0	0	0	1	0	1	1	1	0	11
C73 Thyroid gland	0	1	2	10	16	45	37	57	61	52	62	52	49	45	47	18	0	554
C74 Adrenal gland	11	2	0	1	0	0	0	1	0	0	4	3	0	0	1	1	0	24
C75 Other endocrine glands and related structures	2	1	1	1	1	0	0	3	2	0	1	1	1	2	0	1	0	17
C76 Other and ill-defined sites	2	0	2	2	1	3	1	2	5	8	8	15	13	14	19	14	0	109
C77 Secondary and unspecified malignant neoplasm of lymph nodes	0	0	0	2	2	3	1	2	2	5	8	9	14	11	9	8	0	76
C80 Neoplasm without specification of site	1	0	1	1	5	7	8	22	32	49	95	111	164	142	146	111	3	898
C81 Hodgkin lymphoma	0	5	5	16	12	14	14	11	14	8	17	13	15	14	11	7	0	176
C82 Follicular lymphoma	0	0	0	0	0	0	1	2	3	2	13	4	5	9	3	4	0	46
C83 non-follicular lymphoma	7	12	11	8	7	4	6	5	12	10	15	13	13	11	16	5	0	155
C84 Mature T/NK - cell lymphoma	1	2	2	0	0	0	2	1	4	3	2	2	3	3	5	3	0	33
C85 Other and unspecified types of non-Hodgkin lymphoma	1	1	4	6	8	14	16	8	26	34	41	41	65	55	50	45	0	415
C86 Other specified type of T/NK - cell lymphoma	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	2
C88 Malignant immunoproliferative diseases	0	0	0	0	0	0	1	1	0	1	0	4	1	1	1	1	0	11
C90 Multiple myeloma and malignant plasma cell neoplasms	0	0	0	0	0	1	2	1	5	13	24	46	51	46	44	37	0	270
C91 Lymphoid leukaemia	67	45	27	17	8	10	2	6	7	4	7	7	9	4	8	5	0	233
C92 Myeloid leukaemia	8	1	6	10	15	11	9	20	22	17	28	24	33	17	22	18	0	261
C93 Monocytic leukaemia	4	0	0	0	0	0	0	0	0	1	1	0	2	1	1	2	0	12
C94 Other leukaemia of specified cell type	1	0	0	0	2	1	1	0	0	3	3	0	1	1	5	4	0	22
C95 Leukaemia of unspecified type	4	8	1	9	2	2	1	5	5	1	6	9	6	4	4	7	0	74
C96 Other and unspecified malignant neoplasm of lymphoid, haematopoietic and related tissue	12	1	1	2	0	0	0	1	0	0	0	0	0	0	0	0	0	17
D45 Polycythemia vera	0	0	0	0	0	0	0	0	0	2	0	0	4	1	2	0	0	9
D46 Myelodysplastic syndrome	0	0	0	0	0	0	0	0	1	3	2	2	6	9	11	14	0	48
D47 Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue	0	0	0	0	0	0	0	0	2	1	1	1	2	0	3	4	0	14
All sites	205	108	113	152	150	193	234	386	595	893	1618	2201	2994	2720	2611	2380	29	17582

Table 10: Number of cancers by 5-year age groups and ICD 10 site among females in Sri Lanka, 2021

ICD 10 Site	00-04	10-14	15-19	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Unknown	Total
C00 Lip	0	0	0	0	0	0	1	0	0	3	1	4	4	8	12	9	0	42
C01 Base of tongue	0	0	0	0	0	0	0	0	0	1	2	3	2	2	3	1	0	14
C02 Other and unspecified parts of the tongue	0	0	0	0	0	2	4	2	9	12	27	34	24	17	32	15	2	180
C03 Gum	0	0	0	0	0	0	0	0	0	0	5	4	4	5	3	8	0	29
C04 Floor of mouth	0	0	0	0	1	0	0	0	1	3	1	5	6	3	4	8	0	32
C05 Palate	0	0	0	0	0	0	2	3	5	4	6	9	10	9	10	14	0	72
C06 Other and unspecified	0	0	0	0	0	0	1	2	4	13	33	36	35	61	43	77	0	305
C07 Parotid gland	0	0	1	0	1	3	6	2	9	6	4	14	6	6	5	2	0	65
C08 Other and unspecified salivary gland	0	0	0	1	0	1	0	0	3	0	2	1	2	4	2	1	0	17
C09 Tonsil	0	0	0	0	0	0	0	0	1	1	1	5	6	1	4	4	0	23
C10 Oropharynx	0	0	0	0	0	0	0	0	0	3	2	3	4	1	4	5	0	22
C11 Nasopharynx	0	0	0	1	3	2	0	0	1	0	4	1	2	0	5	1	0	20
C12 Pyriform sinuses	0	0	0	0	0	0	0	1	1	1	0	3	5	4	8	4	0	27
C13 Hypopharynx	0	0	0	0	0	1	1	0	2	1	7	3	12	2	5	5	0	39
C14 Other and ill-defined sites in the lip, oral cavity and Pharynx	0	0	0	0	1	0	0	2	0	0	0	1	4	8	3	6	0	25
C15 Oesophagus	0	0	0	0	0	2	1	8	14	26	65	118	142	169	181	237	2	965
C16 Stomach	0	0	0	0	0	0	1	2	7	12	20	24	28	26	51	33	1	205
C17 Small intestine	0	0	0	0	0	0	1	1	1	5	8	11	5	9	8	12	0	61
C18 Colon	0	0	1	1	6	2	8	30	45	62	92	93	112	101	126	100	0	779
C19 Rectosigmoid junction	0	0	0	0	1	0	0	4	4	6	17	10	24	18	16	25	1	126
C20 Rectum	0	0	0	0	1	1	5	11	29	60	56	82	114	107	105	120	0	691
C21 Anus and anal canal	0	0	0	0	0	0	0	1	3	4	6	5	15	10	15	13	0	72
C22 Liver and intrahepatic bile ducts	11	1	1	0	2	6	1	8	10	9	16	18	38	47	37	50	0	255
C23 Gallbladder	0	0	0	0	0	0	1	2	3	5	3	9	3	9	19	14	0	68
C24 Other and unspecified parts of biliary tract	0	0	0	0	0	2	1	1	3	4	3	9	5	15	8	9	0	60
C25 Pancreas	0	0	2	1	2	1	1	2	3	4	14	21	15	21	21	7	0	115
C26 Other and ill-defined digestive organs	0	0	0	1	0	0	2	0	2	1	4	5	0	5	2	6	0	28
C30 Nasal cavity and middle ear	0	0	0	0	0	0	1	2	0	0	4	5	2	4	2	3	0	23
C31 Accessory sinus	0	0	0	0	0	0	0	0	1	0	1	5	2	1	7	5	0	22
C32 Larynx	0	0	0	0	0	0	0	0	3	4	4	7	11	10	8	10	0	57
C34 Bronchus and lung	0	1	0	0	7	7	7	15	21	24	45	75	106	91	74	76	2	551
C37 Thymus	0	0	0	0	0	1	1	1	2	1	3	3	0	1	0	0	0	13
C38 Heart, mediastinum and pleura	0	0	0	1	1	3	4	1	1	2	2	4	3	3	4	4	0	33
C39 Other and ill-defined sites in the respiratory system and intrathoracic organs	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1
C40 Bones and cartilage of limbs	1	1	10	9	4	9	2	6	6	2	3	1	2	2	0	1	0	59
C41 Bone and articular cartilage of other and unspecified sites	5	2	8	2	3	5	4	5	2	4	5	1	3	6	3	0	0	58
C43 Melanoma of skin	0	0	0	1	0	1	1	1	3	4	5	6	7	10	11	5	0	55
C44 Other malignant neoplasms of skin	0	0	0	1	4	4	5	7	6	7	19	17	24	25	37	52	1	209
C45 Mesothelioma	0	0	0	0	0	0	0	0	1	0	0	0	1	1	2	0	0	5
C46 Kaposi Sarcoma																		
C47 Peripheral nervous and autonomic nerves system	1	0	0	0	2	0	0	0	3	4	1	1	1	1	1	1	0	16
C48 Retroperitoneum and Peritoneum	1	0	0	0	1	0	3	0	3	2	6	10	9	6	6	4	0	51

Table 10 continued...

ICD 10 Site	00-04	10-14	15-19	15-19	20-24	25-29	30-34	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75+	Unknown	Total
C49 Other connective and soft tissue	2	2	3	6	5	8	9	13	8	6	13	13	25	14	21	15	0	163
C50 Breast	0	0	0	0	7	23	92	290	508	641	722	749	814	670	513	453	3	5485
C51 Vulva	0	0	0	0	1	1	0	1	1	1	2	6	5	8	17	16	0	59
C52 Vagina	0	0	0	0	0	0	0	4	0	1	4	5	13	12	10	14	0	63
C53 Cervix uteri	0	0	0	0	1	4	12	43	67	121	166	196	195	166	140	127	0	1238
C54 Corpus Uteri	0	0	0	0	2	4	11	21	36	43	74	135	194	158	121	80	0	879
C55 Uterus, part unspecified	0	0	0	0	0	3	3	10	13	31	29	47	72	56	47	38	0	349
C56 Ovary	4	5	8	18	26	38	30	39	86	144	163	176	183	180	121	85	2	1308
C57 Other and unspecified female genital organs	0	0	0	0	1	0	0	0	3	1	5	5	12	12	3	7	0	49
C58 Placenta	0	0	0	0	3	4	4	5	4	0	1	0	0	0	0	0	0	21
C64 Kidney, except renal pelvis	11	1	1	0	1	1	2	5	7	5	9	11	12	18	16	17	0	117
C65 Renal pelvis	0	0	0	0	0	0	0	0	2	0	3	0	1	0	0	1	0	7
C66 Ureter	0	0	0	0	0	0	0	0	2	0	0	2	2	4	1	4	0	15
C67 Bladder	0	0	0	0	0	1	3	4	5	11	4	18	21	36	43	38	1	185
C68 Other and unspecified urinary organs	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1	2	0	5
C69 Eye and adnexa	9	2	0	0	0	1	1	0	0	1	1	0	2	0	0	1	0	18
C70 Meninges	0	0	0	0	0	1	1	2	11	11	4	3	1	4	3	0	0	41
C71 Brain	7	19	13	4	2	7	6	16	12	25	18	21	28	24	20	7	0	229
C72 Spinal cord, cranial nerves and other parts of central nervous system	4	1	1	0	2	0	1	2	4	0	0	1	1	0	0	1	0	18
C73 Thyroid gland	0	1	9	51	91	180	181	265	277	268	210	149	135	108	64	54	0	2043
C74 Adrenalin gland	9	3	2	0	0	0	0	1	2	0	5	4	3	2	0	0	0	31
C75 Other endocrine glands and related structures	1	0	0	0	1	0	0	1	0	1	5	1	3	1	0	0	0	14
C76 Other and ill-defined sites	3	1	1	1	2	2	0	3	4	4	10	9	8	10	12	17	0	87
C77 Secondary and unspecified malignant neoplasm of lymph nodes	0	1	0	0	0	3	2	3	2	3	6	4	4	11	9	8	0	56
C80 Neoplasm without specification of site	0	0	0	0	6	9	7	21	39	54	70	86	132	100	99	119	3	745
C81 Hodgkin disease	0	4	3	9	16	22	16	9	3	2	5	13	15	8	9	5	0	139
C82 Follicular lymphoma	0	0	0	0	0	1	1	6	3	3	11	4	5	5	5	4	0	48
C83 non-follicular lymphoma	0	7	1	3	4	6	3	8	5	3	11	4	16	10	9	12	0	102
C84 Mature T/NK - cell lymphoma	0	1	4	0	1	4	1	2	3	2	2	4	2	0	0	1	0	27
C85 Other and unspecified non-Hodgkin lymphoma	1	2	3	5	8	20	12	16	11	16	28	33	48	34	28	29	0	294
C86 Other specified type of T/NK - cell lymphoma	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1
C88 Immunoproliferative diseases	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0	3
C90 Multiple myeloma and malignant plasma cell neoplasms	0	0	0	0	0	0	1	4	7	9	24	41	63	57	43	36	0	285
C91 Lymphoid leukaemia	52	25	15	8	3	2	1	4	2	4	3	3	6	12	7	7	0	154
C92 Myeloid leukaemia	8	1	4	7	16	5	11	15	10	21	21	23	27	29	31	21	0	250
C93 Monocytic leukaemia	0	0	1	0	0	0	0	0	0	1	1	1	1	1	1	3	0	10
C94 Other leukaemia of specified cell type	0	0	0	0	0	0	0	3	3	1	2	0	2	1	3	0	0	15
C95 Leukaemia of unspecified type	3	2	3	4	0	2	0	0	3	1	1	2	3	2	7	7	0	40
C96 Other and unspecified malignant neoplasm of lymphoid, haematopoietic and related tissue	5	0	3	0	0	0	0	0	0	0	1	0	0	0	0	0	0	9
D45 Polycythemia vera	0	0	0	0	0	0	0	0	2	0	1	0	1	2	1	2	0	9
D46 Myelodysplastic syndrome	0	0	0	0	1	0	1	0	1	0	3	5	9	6	17	10	0	53
D47 Other neoplasms of uncertain or unknown behaviour of lymphoid, haematopoietic and related tissue	0	0	0	0	0	0	2	0	1	0	1	1	3	4	1	4	0	17
All sites	138	83	98	135	240	405	479	936	1359	1736	2136	2442	2866	2596	2310	2194	18	20171

Table 11: Number of cancers by five-year age group and ICD 10 site categories among males in Sri Lanka, 2021

Cancer Registry (2021)

Population - Sri Lanka 2021

Cases by age group (Period) - Male

S I T E	ALL AGE AGES UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)	
Lip	103	0	-	-	-	1	2	2	4	3	8	12	15	15	13	15	15	0.6	C00	
Tongue	971	-	-	-	-	1	2	8	23	53	90	147	153	170	109	115	96	5.6	C01-02	
Mouth	1613	3	-	-	-	1	2	14	44	55	110	194	245	279	240	210	216	9.3	C03-06	
Salivary glands	127	-	-	-	-	3	1	3	6	4	11	10	17	20	15	19	17	0.7	C07-08	
Tonsil	227	2	-	-	-	-	-	-	-	3	11	27	46	47	35	38	17	1.3	C09	
Other oropharynx	223	0	-	-	-	-	-	-	-	4	15	29	38	49	41	30	17	1.3	C10	
Nasopharynx	39	0	-	-	-	-	-	-	-	-	5	8	5	5	5	2	4	0.2	C11	
Hypopharynx	339	0	-	-	-	-	-	-	-	3	3	28	64	62	62	61	48	2.0	C12-13	
Pharynx unspecified	152	2	-	-	-	-	-	-	-	3	7	16	28	33	30	11	21	0.9	C14	
Oesophagus	1364	5	-	-	-	1	1	7	4	25	57	132	203	307	219	215	188	7.9	C15	
Stomach	420	0	-	-	-	1	2	5	3	12	20	26	69	78	99	54	51	2.4	C16	
Small intestine	77	1	-	-	-	1	1	4	6	1	6	5	16	12	7	12	12	0.4	C17	
Colon	624	1	-	-	-	4	4	8	15	30	37	61	71	107	99	105	80	3.6	C18	
Rectum	898	1	-	-	-	4	3	8	19	35	56	78	112	158	155	124	145	5.2	C19-20	
Anus	91	1	-	-	-	2	3	2	3	4	10	10	18	12	8	18	12	0.5	C21	
Liver	462	0	-	-	-	1	3	2	2	8	16	26	68	88	97	76	67	2.7	C22	
Gallbladder etc.	115	0	-	-	-	1	1	1	2	4	8	11	20	20	19	18	14	0.7	C23-24	
Pancreas	132	0	-	-	-	-	2	1	-	7	11	14	14	23	19	18	21	0.8	C25	
Nose, sinuses etc.	82	0	-	-	-	1	1	1	4	3	5	6	8	15	16	11	9	0.5	C30-31	
Larynx	586	0	-	-	-	1	1	4	7	17	17	74	90	122	116	83	71	3.4	C32	
Trachea, bronchus and lung	1540	2	-	-	-	7	7	20	22	40	106	209	328	341	268	188	188	8.9	C33-34	
Other thoracic organs	56	0	-	-	-	1	1	3	1	3	3	5	2	9	8	8	4	0.3	C37-38	
Bone	145	0	4	7	17	28	12	9	3	12	1	3	10	12	10	5	6	0.8	C40-41	
Melanoma of skin	63	0	-	-	-	1	-	-	-	-	1	7	14	8	8	15	7	0.4	C43	
Other skin	326	0	-	-	-	3	4	3	9	14	20	33	33	57	48	39	61	1.9	C44	
Mesothelioma	13	0	-	-	-	-	-	2	2	-	-	2	3	-	1	1	2	0.1	C45	
Kaposi sarcoma	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.0	C46	
Connective and soft tissue	169	0	7	2	10	4	4	5	7	11	13	8	18	26	23	20	7	1.0	C47, C49	
Breast	124	0	-	-	-	-	1	3	3	7	17	14	15	13	13	20	18	0.7	C50	
Penis	111	0	-	-	-	-	-	2	4	7	11	8	20	21	13	25	25	0.6	C60	
Prostate	1286	1	-	-	-	-	-	-	1	3	4	35	67	178	229	363	405	7.5	C61	
Testis	81	0	6	1	3	10	8	15	10	6	2	1	4	2	1	3	3	0.5	C62	
Other male genital organs	8	0	-	-	-	-	1	1	1	1	-	2	1	1	-	2	2	0.0	C63	
Kidney	346	2	19	6	-	2	1	6	7	10	29	35	39	67	49	42	32	2.0	C64	
Renal pelvis	23	0	-	-	-	-	-	-	-	1	-	2	-	10	4	1	5	0.1	C65	
Ureter	5	0	-	-	-	-	-	-	-	-	-	-	-	1	3	1	-	0.0	C66	
Bladder	731	3	-	-	-	2	7	4	7	9	8	9	46	67	130	132	155	4.2	C67	
Other urinary organs	6	0	-	-	-	-	-	-	-	-	-	-	-	2	1	2	1	0.0	C68	
Eye	39	0	17	-	-	-	1	1	-	2	2	2	1	6	2	4	1	0.2	C69	
Brain, nervous system	328	0	20	14	10	6	13	13	27	33	37	37	42	32	20	23	9	1.9	C70-72	
Thyroid	554	0	1	2	10	16	45	37	57	61	52	62	52	49	45	47	18	3.2	C73	
Adrenal gland	24	0	11	2	1	-	-	-	1	-	-	4	3	-	-	1	1	0.1	C74	
Other endocrine	17	0	2	1	1	1	-	-	3	2	-	1	1	1	2	-	1	0.1	C75	
Hodgkin disease	176	0	5	5	16	12	14	14	11	14	8	17	13	15	14	11	7	1.0	C81	
Non-Hodgkin lymphoma	666	0	21	16	18	16	15	18	25	17	45	49	71	60	86	74	57	3.9	C82-85, C96	
Immunoproliferative diseases	11	0	-	-	-	-	-	-	1	1	-	1	4	1	1	1	1	0.1	C88	
Multiple myeloma	270	0	-	-	-	-	1	2	1	5	13	24	46	51	46	44	37	1.6	C90	
Lymphoid leukaemia	233	0	67	45	27	17	8	10	2	6	7	4	7	9	4	8	5	1.4	C91	
Myeloid leukaemia	295	0	13	1	6	10	17	12	10	20	22	32	24	36	19	28	24	1.7	C92-94	
Leukaemia unspecified	74	0	4	8	1	9	2	1	5	5	1	6	9	6	4	4	7	0.4	C95	
Myeloproliferative disorders	23	0	-	-	-	-	-	-	-	2	3	7	7	6	7	5	4	0.1	MPS	
Myelodysplastic syndromes	48	0	-	-	-	-	-	-	-	7	3	2	2	6	9	11	14	0.3	MDS	
Other and unspecified	1146	3	3	-	3	5	10	13	10	28	41	66	114	146	204	181	138	6.6	O&U	
All sites	17582	29	205	108	113	152	150	193	234	386	595	893	1618	2201	2994	2720	2611	2380	100.0	ALL
All sites but C44	17256	29	205	107	112	152	147	189	231	377	581	873	1585	2168	2937	2672	2572	2319	100.0	ALLbC44

Table built Tue Dec 12 09:03:49 IST 2023 by CanReg5.

Table 12: Number of Cancers by five year age group and ICD 10 site categories among females in Sri Lanka, 2021

Cancer Registry (2021)

Population - Sri Lanka 2021

Cases by age group (Period) - Female

S I T E	ALL AGE AGES UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	(%)	ICD (10th)	
Lip	42	-	-	-	-	-	-	1	-	-	3	1	4	4	8	12	9	0.2	C00	
Tongue	194	2	-	-	-	-	2	4	5	9	13	29	37	26	19	35	16	1.0	C01-02	
Mouth	438	-	-	-	-	-	4	3	2	10	20	45	54	55	78	60	107	2.2	C03-06	
Salivary glands	82	-	-	1	1	1	4	6	2	12	6	1	5	8	10	7	3	0.4	C07-08	
Tonsil	23	-	-	-	-	-	-	-	-	1	1	1	1	1	1	4	4	0.1	C09	
Other oropharynx	22	-	-	-	-	-	-	-	-	-	3	2	3	4	1	4	5	0.1	C10	
Nasopharynx	20	-	-	-	-	-	2	-	-	1	-	4	1	2	-	5	1	0.1	C11	
Hypopharynx	66	-	-	-	-	1	3	2	1	3	2	7	6	17	6	13	9	0.3	C12-13	
Pharynx unspecified	25	-	-	-	-	-	1	1	2	1	-	-	1	4	8	3	6	0.1	C14	
Oesophagus	965	2	-	-	-	-	2	1	8	14	26	65	118	142	169	181	237	4.8	C15	
Stomach	205	1	-	-	-	-	-	1	2	7	12	20	24	28	26	51	33	1.0	C16	
Small intestine	61	0	-	-	-	-	-	1	1	1	5	8	11	5	9	8	12	0.3	C17	
Colon	779	0	-	1	1	6	2	8	30	45	62	92	93	112	101	126	100	3.9	C18	
Rectum	817	0	-	-	-	2	1	5	15	33	66	73	92	138	125	121	145	4.1	C19-20	
Anus	72	0	-	-	-	-	-	-	-	3	4	6	5	15	10	15	13	0.4	C21	
Liver	255	0	1	1	-	2	6	1	8	10	9	16	18	38	47	37	50	1.3	C22	
Gallbladder etc.	128	0	-	-	-	-	2	2	3	6	9	16	18	8	24	27	23	0.6	C23-24	
Pancreas	113	0	-	2	1	2	1	2	2	3	4	14	21	15	21	21	7	0.6	C25	
Nose, sinuses etc.	45	0	-	-	-	-	-	1	2	1	-	4	5	10	4	5	8	0.2	C30-31	
Larynx	57	0	-	-	-	-	-	-	-	3	4	4	7	11	10	8	10	0.3	C32	
Trachea, bronchus and lung	551	2	1	-	-	7	7	7	15	21	24	45	75	107	91	73	76	2.8	C33-34	
Other thoracic organs	46	0	-	-	-	1	4	5	2	3	3	5	7	3	4	4	4	0.2	C37-38	
Bone	117	0	6	3	18	11	7	14	6	11	8	6	8	2	5	8	3	0.6	C40-41	
Melanoma of skin	55	0	-	-	1	-	1	1	1	3	4	5	6	7	10	11	5	0.3	C43	
Other skin	209	1	-	-	1	4	4	5	7	6	7	19	17	24	25	37	52	1.0	C44	
Mesothelioma	5	0	-	-	-	-	-	-	-	1	-	-	-	1	1	2	-	0.0	C45	
Kaposi sarcoma	0	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.0	C46	
Connective and soft tissue	179	0	3	2	3	6	7	8	9	13	11	10	14	14	26	15	22	0.9	C47, C49	
Breast	5485	3	-	-	-	7	23	92	290	508	641	722	749	814	670	513	453	27.5	C50	
Vulva	59	0	-	-	-	1	1	-	1	1	1	2	6	5	8	17	16	0.3	C51	
Vagina	63	0	-	-	-	-	-	-	4	4	1	4	5	13	12	10	14	0.3	C52	
Cervix uteri	1238	0	-	-	-	1	4	12	43	67	121	166	196	195	166	140	127	6.2	C53	
Corpus uteri	879	0	-	-	-	2	4	11	21	36	43	74	135	194	158	121	80	4.4	C54	
Uterus unspecified	349	0	-	-	-	3	3	10	31	31	29	47	72	56	47	38	38	1.7	C55	
Ovary	1308	2	4	5	8	18	26	38	30	86	144	163	176	183	180	121	85	6.6	C56	
Other female genital organs	49	0	-	-	-	1	-	-	-	3	5	5	5	12	12	3	7	0.2	C57	
Placenta	21	0	-	-	-	3	4	4	5	4	-	1	-	-	-	-	-	0.1	C58	
Kidney	117	0	1	1	-	1	1	2	5	7	5	9	11	12	18	16	17	0.6	C64	
Renal pelvis	7	0	-	-	-	-	-	-	-	2	-	3	-	1	-	1	-	0.0	C65	
Ureter	15	0	-	-	-	-	-	-	-	2	-	3	-	2	4	1	4	0.1	C66	
Bladder	185	1	-	-	-	-	1	3	4	5	11	4	18	21	36	43	38	0.9	C67	
Other urinary organs	5	0	-	-	-	-	-	-	-	-	-	-	-	-	1	1	2	0.0	C68	
Eye	18	0	9	2	-	-	1	1	-	-	1	1	-	2	-	-	1	0.1	C69	
Brain, nervous system	288	0	11	20	14	4	8	8	20	27	36	22	25	30	28	23	8	1.4	C70-72	
Thyroid	2043	0	1	9	51	91	180	181	265	277	268	210	149	135	108	64	54	10.2	C73	
Adrenal gland	31	0	3	2	-	-	-	-	1	2	-	5	4	3	2	-	-	0.2	C74	
Other endocrine	14	0	1	-	-	-	-	-	1	-	1	5	1	3	-	-	-	0.1	C75	
Hodgkin disease	139	0	4	3	9	16	22	16	9	3	2	5	13	15	8	9	5	0.7	C81	
Non-Hodgkin lymphoma	480	0	6	10	11	8	13	17	32	22	24	53	45	71	49	42	46	2.4	C82-85, C96	
Immunoproliferative diseases	3	0	-	-	-	-	-	-	-	-	-	-	-	1	-	-	1	0.0	C88	
Multiple myeloma	285	0	-	-	-	-	-	1	4	7	9	24	41	63	57	43	36	1.4	C90	
Lymphoid leukaemia	154	0	52	25	15	8	3	2	1	4	2	4	3	6	12	7	7	0.8	C91	
Myeloid leukaemia	275	0	8	1	5	7	16	5	11	18	13	23	24	30	31	35	24	1.4	C92-94	
Leukaemia unspecified	40	0	3	2	3	4	-	2	-	3	1	1	2	3	2	7	7	0.2	C95	
Myeloproliferative disorders	26	0	-	-	-	-	-	2	-	3	-	2	1	4	6	2	6	0.1	MPD	
Myelodysplastic syndromes	53	0	-	-	-	-	-	1	-	1	-	3	5	9	6	17	10	0.3	MDS	
Other and unspecified	969	3	4	2	1	2	9	14	27	50	64	96	114	152	133	129	155	4.9	O&U	
All sites	20171	18	138	83	98	135	240	405	479	936	1359	1736	2136	2442	2866	2596	2310	2194	100.0	ALL
All sites but C44	19962	17	138	83	98	134	236	401	474	929	1353	1729	2117	2425	2842	2571	2273	2142	100.0	ALL but C44

Table built Tue Dec 12 09:03:49 IST 2023 by CanReg5.

Table 13: Age Specific Incidence Rate, Crude Incidence Rate, Age Standardized Incidence Rate per 100 000 population and Cumulative Risk of cancers by five Year age group and ICD 10 site categories among males in Sri Lanka, 2021

Cancer Registry (2021)

Population - Sri Lanka 2021

Incidence per 100,000 by age group (Period) - Male

S I T E	ALL AGE AGES UNK	0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75+	CRUDE RATE (%)	CUMCUM ASR 0-64	ICD (10th)			
Lip	103	-	-	-	-	0.1	0.2	0.5	0.4	1.2	1.9	2.8	3.2	4.2	7.6	6.2	1.0	0.6	0.05	0.11	C00		
Tongue	971	-	-	-	0.1	0.2	0.2	0.9	3.1	7.4	13.4	23.3	28.1	36.8	58.3	39.4	9.1	5.6	0.57	1.04	C01-02		
Mouth	1613	-	-	-	-	0.1	0.2	1.6	5.9	7.6	16.4	30.7	45.0	60.4	78.0	106.5	15.0	9.3	0.84	1.77	C03-06		
Salivary glands	127	-	-	0.1	-	-	-	0.3	0.8	0.6	1.6	1.6	3.1	4.3	4.9	9.6	7.0	1.2	0.7	0.06	0.14	C07-08	
Tonsil	227	-	-	0.1	-	-	-	-	-	0.4	1.6	4.3	8.4	10.2	11.4	19.3	7.0	2.1	1.3	0.13	0.28	C09	
Other oropharynx	223	-	-	-	-	-	-	-	-	0.6	2.2	4.6	7.0	10.6	13.3	15.2	7.0	2.1	1.3	0.12	0.27	C10	
Nasopharynx	39	0.1	-	0.1	0.2	0.1	-	-	-	0.7	1.3	0.9	1.1	1.6	1.0	1.0	1.6	0.4	0.2	0.02	0.04	C11	
Pharynx	339	-	-	-	-	-	0.1	0.5	0.1	0.7	0.4	4.4	11.8	13.4	20.1	30.9	19.7	3.2	2.0	0.16	0.41	C12-13	
Pharynx unspecified	152	-	-	-	-	0.1	-	-	0.4	1.0	2.5	5.1	7.1	9.7	5.6	8.6	1.4	0.9	0.08	0.16	C14		
Oesophagus	1364	-	-	-	-	0.1	0.1	0.8	0.5	3.5	8.5	20.9	37.3	66.4	71.1	109.0	77.2	12.7	7.9	0.69	1.60	C15	
Stomach	420	-	-	-	-	0.1	0.2	0.6	0.4	1.7	3.0	4.1	12.7	16.9	32.2	27.4	20.9	3.9	2.4	0.20	0.50	C16	
Small intestine	77	-	-	-	-	0.1	-	-	0.1	0.6	0.9	0.8	2.9	2.6	2.3	6.1	4.9	0.7	0.4	0.04	0.08	C17	
Colon	624	-	0.1	-	0.1	0.5	0.5	0.9	2.0	4.2	5.3	9.6	13.0	23.2	32.2	53.2	32.9	5.8	3.6	0.30	0.73	C18	
Rectum	898	-	-	-	-	0.5	0.4	0.9	2.5	4.9	8.3	12.3	20.6	34.2	50.4	62.9	59.6	8.4	5.2	0.42	0.99	C19-20	
Anus	91	-	-	-	-	0.2	0.3	0.3	0.4	0.6	1.6	1.8	3.9	3.9	4.1	7.4	7.4	0.8	0.5	0.20	0.09	C21	
Liver	462	0.7	-	-	0.1	0.2	0.1	0.3	0.3	1.1	2.4	4.1	12.5	19.0	31.5	38.5	27.5	4.3	2.7	0.05	0.56	C22	
Gallbladder etc.	115	-	-	-	-	-	-	0.1	-	0.6	1.2	1.7	3.7	4.3	6.2	9.1	5.8	1.1	0.7	0.06	0.13	C23-24	
Pancreas	132	0.1	-	0.1	-	-	0.2	0.1	-	1.0	1.6	2.2	2.6	5.0	6.2	9.1	8.6	1.2	0.8	0.06	0.14	C25	
Nose, sinuses etc.	82	0.1	-	-	0.1	0.2	-	0.1	0.5	0.4	0.7	0.9	1.5	3.2	5.2	5.6	3.7	0.8	0.5	0.04	0.09	C30-31	
Larynx	586	-	-	-	-	0.1	0.1	0.1	0.5	1.0	2.5	11.7	16.5	26.4	37.7	42.1	29.2	5.5	3.4	0.29	0.69	C32	
Trachea, bronchus and lung	1540	-	-	-	-	0.9	0.2	0.8	2.7	3.1	5.9	16.8	38.4	71.0	110.8	135.9	77.2	14.4	8.9	0.70	1.93	C33-34	
Other thoracic organs	56	0.1	-	0.1	0.7	0.1	0.1	0.3	0.1	0.4	0.4	0.8	0.4	1.9	2.6	4.1	1.6	0.5	0.3	0.03	0.06	C37-38	
Bone	145	0.4	0.7	1.9	3.1	1.5	1.1	0.3	1.6	0.1	0.4	1.6	2.2	2.2	1.6	3.0	2.5	1.4	0.8	0.09	0.11	C40-41	
Melanoma of skin	63	-	-	0.1	-	-	-	0.2	-	-	0.1	1.1	2.6	1.7	2.6	7.6	2.9	0.6	0.4	0.03	0.08	C43	
Other skin	326	-	0.1	0.1	-	0.4	0.5	0.3	1.2	1.9	3.0	5.2	6.1	12.3	15.6	19.8	25.1	3.0	1.9	0.16	0.33	C44	
Mesothelioma	13	-	-	-	-	-	-	0.2	0.3	-	-	0.3	0.6	-	0.3	0.5	0.8	0.1	0.1	0.01	0.01	C45	
Kaposi sarcoma	0	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.0	0.0	0.00	0.00	C46	
Connective and soft tissue	169	0.7	0.2	1.1	0.4	0.5	0.6	0.8	1.5	1.8	1.2	2.8	4.8	5.0	6.5	3.5	1.6	1.6	1.0	0.11	0.16	C47,C49	
Breast	124	-	-	-	-	-	0.1	0.3	0.4	1.0	2.5	2.2	2.8	2.8	4.2	10.1	7.4	1.2	0.7	0.06	0.13	C50	
Penis	111	-	-	-	-	-	-	0.2	-	0.6	1.0	1.7	1.5	4.3	6.8	6.6	10.3	1.0	0.6	0.05	0.11	C60	
Prostate	1286	-	-	-	-	-	-	-	0.1	0.4	0.6	5.5	12.3	38.5	74.4	184.0	166.3	12.0	7.5	0.29	1.58	C61	
Testis	81	0.6	0.1	0.3	1.1	1.0	1.9	1.2	0.8	0.3	0.1	0.6	0.4	0.2	1.0	1.5	2.5	0.8	0.5	0.04	0.06	C62	
Other male genital organs	8	-	-	-	-	-	-	0.1	-	0.1	-	0.3	0.2	0.2	-	-	0.8	0.1	0.0	0.00	0.00	C63	
Kidney	346	2	0.6	-	-	0.2	0.1	0.7	0.9	1.4	4.3	5.5	7.2	14.5	15.9	21.3	13.1	3.2	2.0	0.19	0.38	C64	
Renal pelvis	23	-	-	-	-	-	-	-	-	0.1	-	0.3	-	0.2	1.3	0.5	2.1	0.2	0.1	0.01	0.02	C65	
Ureter	5	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.0	0.0	0.00	0.01	C66	
Bladder	731	-	0.1	-	0.2	0.1	0.5	0.1	1.2	1.1	1.3	7.3	12.3	28.1	42.9	78.6	66.9	6.8	4.2	0.26	0.87	C67	
Other urinary organs	6	-	-	-	-	-	-	-	-	-	-	-	-	0.4	0.3	1.0	0.4	0.1	0.0	0.00	0.01	C68	
Eye	39	1.8	-	-	-	0.1	0.1	-	0.3	-	0.3	0.3	0.2	1.3	0.6	2.0	0.4	0.4	0.2	0.02	0.04	C69	
Brain, nervous system	328	2.1	1.0	1.5	1.1	0.7	1.6	1.5	2.8	4.6	4.6	4.9	7.7	6.9	6.5	11.7	3.7	3.1	1.9	0.21	0.30	C70-72	
Thyroid	554	-	0.1	0.2	1.1	2.0	5.6	4.3	7.6	8.5	7.7	9.8	9.6	10.6	14.6	23.8	7.4	5.2	3.2	0.34	0.53	C73	
Adrenal gland	24	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.5	0.4	0.2	0.1	0.01	0.02	C74	
Other endocrine	17	-	-	-	-	-	-	-	-	0.4	0.3	-	0.2	0.2	0.6	-	0.4	0.2	0.1	0.01	0.01	C75	
Hodgkin disease	176	-	0.5	0.6	1.8	1.5	1.7	1.6	1.5	1.9	1.2	2.7	2.4	3.2	4.5	5.6	2.9	1.6	1.0	0.10	0.15	C81	
Non-Hodgkin lymphoma	666	2.2	1.7	2.0	1.8	1.9	2.2	2.9	2.3	6.3	7.3	11.2	11.0	18.6	25.3	37.5	23.4	6.2	3.9	0.36	0.67	C82-85,C96	
Immunoproliferative diseases	11	-	-	-	-	-	-	-	0.1	0.1	-	0.7	0.2	0.3	0.5	0.4	-	0.1	0.1	0.01	0.01	C88	
Multiple myeloma	270	-	-	-	-	-	-	0.1	0.2	0.1	0.7	1.9	3.8	8.4	11.0	14.9	22.3	2.5	1.6	0.13	0.32	C90	
Lymphoid leukaemia	233	0	4.7	3.0	1.9	1.0	1.2	0.2	0.8	1.0	0.6	1.1	1.3	1.9	1.3	4.1	2.1	2.2	1.4	0.13	0.16	C91	
Myeloid leukaemia	295	1.4	0.1	0.7	1.1	2.1	1.5	1.2	2.7	3.1	3.1	5.1	4.4	7.8	6.2	14.2	9.9	2.8	1.7	0.17	0.27	C92-94	
Leukaemia unspecified	74	0.4	0.8	0.1	1.0	0.2	0.2	0.1	0.7	0.1	0.9	1.7	1.3	1.3	2.0	2.0	2.9	0.7	0.4	0.04	0.06	C95	
Myeloproliferative disorders	23	-	-	-	-	-	-	-	-	0.3	0.4	0.2	0.2	1.3	0.3	2.5	1.6	0.2	0.1	0.01	0.03	C96	
Myelodysplastic syndromes	48	-	-	-	-	-	-	-	-	0.1	0.4	0.3	0.4	1.3	2.9	5.6	5.8	0.4	0.3	0.01	0.06	C97	
Other and unspecified	1146	3	0.3	-	0.3	0.6	1.2	1.6	1.2	3.8	5.7	9.8	18.0	26.8	44.2	58.8	91.8	10.7	6.6	0.57	1.32	O&U	
All sites	17582	29	21.4	11.2	12.5	17.0	18.6	23.9	27.0	51.7	82.7	132.8	256.0	404.3	648.0	883.6	1323.7	163.9	8.55	19.60	155.1	ALL	
All sites but C44	17256	29	21.4	11.1	12.4	17.0	18.2	23.4	26.6	50.5	80.8	129.8	250.7	398.2	635.7	868.1	1303.9	160.9	100.0	8.39	19.27	152.2	ALLbc44

Reference population: WHO Standard Population

Table built Tue Dec 12 09:06:01 IST 2023 by CanReg5.

Table 15: Lip, tongue and mouth cancer incidence data in Sri Lanka, 2021

Group	Number	%	ASR	Cum. Rate
Male	2687	15.5	23.1	2.87
Female	674	3.4	4.8	0.61

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site		Male	Female
C000	External upper lip	7	4
C001	External lower lip	29	11
C002	External lip, unspecified	8	2
C003	Upper lip, inner aspect	4	3
C004	Lower lip, inner aspect	18	9
C005	Lip, unspecified, inner aspect	4	2
C006	Commissure of lip	20	2
C008	Overlapping lesion of lip	1	0
C009	Lip, unspecified	12	9
C01	Malignant neoplasm of base of tongue	192	14
C020	Dorsal surface of tongue	25	11
C021	Border of tongue	256	69
C022	Ventral surface of tongue	24	6
C023	Anterior two-thirds of tongue, part unspecified	10	5
C024	Lingual tonsil	4	0
C028	Overlapping lesion of tongue	17	2
C029	Tongue, unspecified	443	87
C030	Upper gum	24	8
C031	Lower gum	55	11
C039	Gum, unspecified	34	10
C040	Anterior floor of mouth	19	4
C041	Lateral floor of mouth	40	8
C048	Overlapping lesion of floor of mouth	8	1
C049	Floor of mouth, unspecified	138	19
C050	Hard palate	46	33
C051	Soft palate	147	16
C052	Uvula	12	3
C058	Overlapping lesion of palate	11	3
C059	Palate, unspecified	62	17
C060	Cheek mucosa	614	208
C061	Vestibule of mouth	44	15
C062	Retromolar area	122	13
C068	Overlapping lesion of other and unspecified parts of mouth	33	13
C069	Mouth, unspecified	204	56
Total		2687	674

Table 15 continued...

ICD 10 code and histology		Male	Female
8000	Neoplasm, malignant	123	57
8001	Tumor cells, malignant	1	1
8002	Malignant tumor, small cell type	2	0
8004	Malignant tumor, spindle cell type	0	1
8010	Carcinoma, NOS	136	41
8020	Carcinoma, undifferentiated, NOS	2	0
8022	Pleomorphic carcinoma	1	0
8032	Spindle cell carcinoma, NOS	9	3
8050	Papillary carcinoma, NOS	1	1
8051	Verrucous carcinoma, NOS	43	15
8052	Papillary squamous cell carcinoma	4	0
8070	Squamous cell carcinoma, NOS	2233	520
8071	Squamous cell carcinoma, keratinizing, NOS	50	9
8074	Squamous cell carcinoma, spindle cell	2	0
8076	Squamous cell carcinoma, microinvasive	18	2
8082	Lymphoepithelial carcinoma	1	0
8083	Basaloid squamous cell carcinoma	8	1
8084	Squamous cell carcinoma, clear cell type	1	0
8123	Basaloid carcinoma	3	0
8140	Adenocarcinoma, NOS	18	7
8147	Basal cell adenocarcinoma	1	0
8200	Adenoid cystic carcinoma	10	6
8246	Neuroendocrine carcinoma, NOS	2	0
8260	Papillary adenocarcinoma, NOS	1	0
8430	Mucoepidermoid carcinoma	6	6
8440	Cystadenocarcinoma, NOS	1	0
8480	Mucinous adenocarcinoma	2	0
8550	Acinar cell carcinoma	0	1
8560	Adenosquamous carcinoma	1	0
8720	Malignant melanoma, NOS (except juvenile melanoma)	1	1
8800	Sarcoma, NOS	1	1
8890	Leiomyosarcoma, NOS	2	0
8894	Angiomyosarcoma	2	0
8900	Rhabdomyosarcoma, NOS	0	1
9120	Hemangiosarcoma	1	0
Total		2687	674




Figure 21: Age Specific Incidence Rates of Lip, tongue and mouth cancer in Sri Lanka, 2021




Figure 22: Age Standardized Incidence Rates of Lip, tongue and mouth cancer in Sri Lanka, 2005-2021

Table 16: Pharyngeal cancer incidence data in Sri Lanka, 2021

Group	Number	%	ASR	Cum.Rate
Male	980	5.7	8.5	1.15
Female	156	0.7	1.1	0.15

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site		Male	Female
C090	Tonsillar fossa	24	0
C091	Tonsillar pillar (anterior)(posterior)	8	1
C098	Overlapping lesion of tonsil	4	0
C099	Tonsil, unspecified	191	22
C100	Vallecula	100	8
C101	Anterior surface of epiglottis	34	3
C102	Lateral wall of oropharynx	3	0
C103	Posterior wall of oropharynx	4	1
C104	Branchial cleft	1	0
C108	Overlapping lesion of oropharynx	4	0
C109	Oropharynx, unspecified	77	10
C110	Superior wall of nasopharynx	1	1
C111	Posterior wall of nasopharynx	1	0
C113	Anterior wall of nasopharynx	3	0
C119	Nasopharynx, unspecified	34	19
C12	Malignant neoplasm of piriform sinus	232	27
C130	Post cricoid region	33	29
C131	Aryepiglottic fold, hypopharyngeal aspect	30	1
C132	Posterior wall of hypopharynx	3	2
C138	Overlapping lesion of hypopharynx	6	2
C139	Hypopharynx, unspecified	35	5
C140	Pharynx, unspecified	129	21
C148	Overlapping lesion of lip, oral cavity and pharynx	23	4
Total		980	156

Table 16 continued...

ICD 10 code and histology		Male	Female
8000	Neoplasm, malignant	57	13
8010	Carcinoma, NOS	84	23
8015	Glassy cell carcinoma	2	0
8032	Spindle cell carcinoma, NOS	13	1
8033	Pseudosarcomatous carcinoma	1	0
8050	Papillary carcinoma, NOS	0	1
8052	Papillary squamous cell carcinoma	1	0
8070	Squamous cell carcinoma, NOS	765	103
8071	Squamous cell carcinoma, keratinizing, NOS	17	4
8072	Squamous cell carcinoma, large cell, nonkeratinizing	5	1
8074	Squamous cell carcinoma, spindle cell	1	2
8076	Squamous cell carcinoma, microinvasive	5	0
8082	Lymphoepithelial carcinoma	3	2
8083	Basaloid squamous cell carcinoma	6	0
8140	Adenocarcinoma, NOS	5	1
8141	Scirrhous adenocarcinoma	0	1
8200	Adenoid cystic carcinoma	3	2
8251	Alveolar adenocarcinoma	1	0
8430	Mucoepidermoid carcinoma	3	0
8560	Adenosquamous carcinoma	1	0
8562	Epithelial-myoepithelial carcinoma	0	1
8720	Malignant melanoma, NOS (except juvenile melano ma)	2	0
8801	Spindle cell sarcoma	1	0
8805	Undifferentiated sarcoma	1	0
8851	Liposarcoma, well differentiated	1	0
8890	Leiomyosarcoma, NOS	0	1
8900	Rhabdomyosarcoma, NOS	1	0
8980	Carcinosarcoma, NOS	1	0
Total		980	156




Figure 23: Age Specific Incidence Rate of Pharyngeal cancer in Sri Lanka, 2021




Figure 24: Age Standardized Incidence Rates of Pharyngeal cancer in Sri Lanka, 2012-2021

Table 17: Oesophageal cancer incidence data in Sri Lanka, 2021

Group	Number	%	ASR	Cum.Rate
Male	1364	7.9	11.9	1.60
Female	965	4.8	6.8	0.90

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site		Male	Female
C150	Cervical part of oesophagus	37	34
C151	Thoracic part of oesophagus	6	9
C152	Abdominal part of oesophagus	18	15
C153	Upper third of oesophagus	36	20
C154	Middle third of oesophagus	114	114
C155	Lower third of oesophagus	210	118
C158	Overlapping lesion of oesophagus	1	7
C159	Oesophagus, unspecified	942	648
Total		1364	965

ICD 10 code and histology		Male	Female
8000	Neoplasm, malignant	59	32
8005	Malignant tumor, clear cell type	1	0
8010	Carcinoma, NOS	151	115
8013	Large cell neuroendocrine carcinoma	1	0
8020	Carcinoma, undifferentiated, NOS	2	0
8032	Spindle cell carcinoma, NOS	4	11
8041	Small cell carcinoma, NOS	1	0
8052	Papillary squamous cell carcinoma	0	1
8070	Squamous cell carcinoma, NOS	790	714
8071	Squamous cell carcinoma, keratinizing, NOS	12	9
8072	Squamous cell carcinoma, large cell, nonkeratinizing	1	0
8073	Squamous cell carcinoma, small cell, nonkeratinizing	0	3
8075	Squamous cell carcinoma, adenoid	1	0
8076	Squamous cell carcinoma, microinvasive	0	2
8083	Basaloid squamous cell carcinoma	2	0
8140	Adenocarcinoma, NOS	310	68
8144	Adenocarcinoma, intestinal type	2	1
8230	Solid carcinoma, NOS	0	1
8246	Neuroendocrine carcinoma, NOS	3	5
8320	Granular cell carcinoma	1	0
8480	Mucinous adenocarcinoma	2	0
8490	Signet ring cell carcinoma	19	2
8560	Adenosquamous carcinoma	2	1
Total		1364	965




Figure 25: Age Specific Incidence Rates of Oesophageal cancer in Sri Lanka, 2021




Figure 26: Age Standardized Incidence Rates of Oesophageal cancer in Sri Lanka, 2005 -2021

Table 18: Stomach cancer incidence data in Sri Lanka, 2021

Group	Number	%	ASR	Cum. Rate
Male	420	2.4	3.7	0.50
Female	205	1	1.5	0.21

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site		Male	Female
C160	Cardia	114	45
C161	Fundus of stomach	11	3
C162	Body of stomach	2	2
C163	Pyloric antrum	32	12
C164	Pylorus	35	26
C165	Lesser curvature of stomach, unspecified	2	6
C166	Greater curvature of stomach, unspecified	4	3
C168	Overlapping lesion of stomach	2	3
C169	Stomach, unspecified	218	105
Total		420	205

ICD 10 code and histology		Male	Female
8000	Neoplasm, malignant	21	15
8001	Tumor cells, malignant	0	1
8002	Malignant tumor, small cell type	1	0
8004	Malignant tumor, spindle cell type	1	2
8010	Carcinoma, NOS	41	26
8032	Spindle cell carcinoma, NOS	1	3
8050	Papillary carcinoma, NOS	1	0
8070	Squamous cell carcinoma, NOS	22	21
8071	Squamous cell carcinoma, keratinizing, NOS	1	0
8083	Basaloid squamous cell carcinoma	0	1
8140	Adenocarcinoma, NOS	256	91
8144	Adenocarcinoma, intestinal type	12	7
8153	Gastrinoma, malignant	6	1
8211	Tubular adenocarcinoma	1	2
8244	Composite carcinoid	1	0
8246	Neuroendocrine carcinoma, NOS	4	2
8480	Mucinous adenocarcinoma	5	2
8490	Signet ring cell carcinoma	28	11
8550	Acinar cell carcinoma	1	0
8560	Adenosquamous carcinoma	5	0
8588	Spindle epithelial tumour with thymus-like element	0	1
8936	Gastrointestinal stromal sarcoma	12	19
Total		420	205




Figure 27: Age Specific Incidence Rates of Stomach cancer in Sri Lanka, 2021




Figure 28: Age Standardized Incidence Rates of Stomach cancer in Sri Lanka, 2005-2021

Table 19: Colon and rectum cancer incidence data in Sri Lanka, 2021

Group	Number	%	ASR	Cum.Rate
Male	1522	8.8	13.3	1.70
Female	1596	8	11.6	1.47

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site		Male	Female
C180	Caecum	55	52
C181	Appendix	33	37
C182	Ascending colon	52	54
C183	Hepatic flexure	14	13
C184	Transverse colon	21	46
C185	Splenic flexure	6	10
C186	Descending colon	18	37
C187	Sigmoid colon	211	262
C188	Overlapping lesion of colon	4	3
C189	Colon, unspecified	210	265
C19	Malignant neoplasm of rectosigmoid junction	113	126
C20	Malignant neoplasm of rectum	785	691
Total		1522	1596

Table 19 continued...

ICD 10 code and histology		Male	Female
8000	Neoplasm, malignant	71	67
8002	Malignant tumor, small cell type	0	1
8003	Malignant tumor, giant cell type	0	1
8010	Carcinoma, NOS	128	105
8020	Carcinoma, undifferentiated, NOS	1	0
8032	Spindle cell carcinoma, NOS	4	0
8050	Papillary carcinoma, NOS	1	2
8070	Squamous cell carcinoma, NOS	22	21
8072	Squamous cell carcinoma, large cell, nonkeratinizing	1	1
8083	Basaloid squamous cell carcinoma	0	3
8140	Adenocarcinoma, NOS	1164	1267
8141	Scirrhous adenocarcinoma	0	1
8144	Adenocarcinoma, intestinal type	17	26
8190	Trabecular adenocarcinoma	1	0
8210	Adenocarcinoma in adenomatous polyp	1	0
8211	Tubular adenocarcinoma	6	2
8240	Carcinoid tumor, NOS	1	3
8243	Goblet cell carcinoid	2	3
8245	Adenocarcinoid tumuor	0	2
8246	Neuroendocrine carcinoma, NOS	15	14
8249	A typical carcinoid tumour	1	0
8260	Papillary adenocarcinoma, NOS	0	2
8261	Adenocarcinoma in villous adenoma	1	0
8262	Villous adenocarcinoma	0	1
8263	Adenocarcinoma in tubulovillous adenoma	2	6
8430	Mucoepidermoid carcinoma	0	2
8480	Mucinous adenocarcinoma	60	42
8490	Signet ring cell carcinoma	10	16
8510	Medullary carcinoma, NOS	1	0
8550	Acinar cell carcinoma	3	0
8560	Adenosquamous carcinoma	1	0
8720	Malignant melanoma, NOS (except juvenile melano ma)	1	0
8746	Mucosal lentiginous melanoma	1	0
8800	Sarcoma, NOS	2	1
8936	Gastrointestinal stromal sarcoma	4	7
Total		1522	1596




Figure 29: Age Specific Incidence Rates of Colon and rectum cancer in Sri Lanka, 2021




Figure 30: Age Standardized Incidence Rates of Colon and rectum cancer in Sri Lanka, 2005 -2021

Table 20: Laryngeal cancer incidence data in Sri Lanka, 2021

Group	Number	%	ASR	Cum.Rate
Male	586	3.4	5.1	0.69
Female	57	0.3	0.4	0.05

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site		Male	Female
C320	Glottis	242	21
C321	Supraglottis	226	19
C322	Subglottis	6	2
C323	Laryngeal cartilage	19	7
C328	Overlapping lesion of larynx	2	0
C329	Larynx, unspecified	91	8
Total		586	57

ICD 10 code and histology		Male	Female
8000	Neoplasm, malignant	12	1
8010	Carcinoma, NOS	25	3
8032	Spindle cell carcinoma, NOS	1	0
8070	Squamous cell carcinoma, NOS	527	49
8071	Squamous cell carcinoma, keratinizing, NOS	11	0
8072	Squamous cell carcinoma, large cell, nonkeratinizing	1	0
8074	Squamous cell carcinoma, spindle cell	0	1
8078	Squamous cell carcinoma with horn formation	0	1
8083	Basaloid squamous cell carcinoma	2	0
8140	Adenocarcinoma, NOS	2	1
8200	Adenoid cystic carcinoma	2	0
8246	Neuroendocrine carcinoma, NOS	1	0
8560	Adenosquamous carcinoma	1	0
8806	Desmoplastic small round cell tumour	0	1
8890	Leiomyosarcoma, NOS	1	0
Total		586	57




Figure 31: Age Specific Incidence Rates of Laryngeal cancer in Sri Lanka, 2021




Figure 32: Age Standardized Incidence Rates of Laryngeal cancer in Sri Lanka, 2005-2021

Table 21: Trachea, bronchus and lung cancer incidence data in Sri Lanka, 2021

Group	Number	%	ASR	Cum. Rate
Male	1540	8.9	13.7	1.93
Female	551	2.8	4.0	0.51

ASR - Age Standardized Incidence Rate per 100,000 population
 Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site		Male	Female
C33	Trachea	7	1
C340	Main bronchus	90	24
C341	Upper lobe, bronchus or lung	166	40
C342	Middle lobe, bronchus or lung	20	8
C343	Lower lobe, bronchus or lung	73	23
C348	Overlapping lesion of bronchus and lung	7	1
C349	Bronchus or lung, unspecified	1184	455
Total		1540	551

ICD 10 code and histology		Male	Female
8000	Neoplasm, malignant	173	57
8001	Tumor cells, malignant	1	0
8002	Malignant tumor, small cell type	1	0
8004	Malignant tumor, spindle cell type	2	1
8010	Carcinoma, NOS	209	63
8011	Epithelioma, malignant	1	1
8012	Large cell carcinoma, NOS	3	1
8013	Large cell neuroendocrine carcinoma	3	0
8020	Carcinoma, undifferentiated, NOS	1	1
8022	Pleomorphic carcinoma	2	0
8032	Spindle cell carcinoma, NOS	5	1
8033	Pseudosarcomatous carcinoma	0	1
8041	Small cell carcinoma, NOS	107	9
8043	Small cell carcinoma, fusiform cell	2	0
8046	Non-small cell carcinoma	301	87
8050	Papillary carcinoma, NOS	1	0
8070	Squamous cell carcinoma, NOS	237	36
8071	Squamous cell carcinoma, keratinizing, NOS	2	2

Table 21 continued...

ICD 10 code and histology		Male	Female
8072	Squamous cell carcinoma, large cell, nonkeratinizing	1	0
8078	Squamous cell carcinoma with horn formation	0	1
8083	Basaloid squamous cell carcinoma	1	0
8140	Adenocarcinoma, NOS	428	240
8141	Scirrhus adenocarcinoma	0	1
8143	Superficial spreading adenocarcinoma	1	0
8200	Adenoid cystic carcinoma	5	4
8240	Carcinoid tumor, NOS	3	10
8246	Neuroendocrine carcinoma, NOS	6	0
8249	A typical carcinoid tumour	2	2
8250	Bronchiolo-alveolar adenocarcinoma, NOS	10	8
8251	Alveolar adenocarcinoma	1	0
8252	Bronchiolo-alveolar carcinoma, non-mucinous	1	1
8260	Papillary adenocarcinoma, NOS	3	4
8310	Clear cell adenocarcinoma, NOS	0	1
8430	Mucoepidermoid carcinoma	0	1
8480	Mucinous adenocarcinoma	10	7
8510	Medullary carcinoma, NOS	0	0
8550	Acinar cell carcinoma	5	3
8560	Adenosquamous carcinoma	5	2
8800	Sarcoma, NOS	2	1
8802	Giant cell sarcoma (except of bone)	1	0
8805	Undifferentiated sarcoma	0	1
8840	Myxosarcoma	1	0
8890	Leiomyosarcoma, NOS	1	2
8973	Pleuropulmonary blastoma	0	1
8980	Carcinosarcoma, NOS	2	1
Total		1540	551




Figure 33: Age Specific Incidence Rates of Trachea, bronchus and lung cancer in Sri Lanka, 2021




Figure 34: Age Standardized Incidence Rates of Trachea, bronchus and lung cancer in Sri Lanka, 2005 - 2021

Table 22: Skin cancer incidence data in Sri Lanka, 2021

Group	Number	%	ASR	Cum. Rate
Male	389	2.3	3.4	0.41
Female	264	1.3	1.9	0.24

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site		Male	Female
C430	Malignant melanoma of lip	0	4
C433	Malignant melanoma of other and unspecified parts of face	2	2
C435	Malignant melanoma of trunk	3	5
C436	Malignant melanoma of upper limb, including shoulder	5	4
C437	Malignant melanoma of lower limb, including hip	30	19
C438	Overlapping malignant melanoma of skin	1	0
C439	Malignant melanoma of skin, unspecified	22	21
C440	Skin of lip	6	4
C441	Skin of eyelid, including canthus	16	13
C442	Skin of ear and external auricular canal	12	12
C443	Skin of other and unspecified parts of face	28	25
C444	Skin of scalp and neck	52	29
C445	Skin of trunk	33	30
C446	Skin of upper limb, including shoulder	17	14
C447	Skin of lower limb, including hip	85	41
C449	Malignant neoplasm of skin, unspecified	77	41
Total		389	264

ICD 10 code and histology		Male	Female
8000	Neoplasm, malignant	13	7
8001	Tumor cells, malignant	0	1
8010	Carcinoma, NOS	12	14
8020	Carcinoma, undifferentiated, NOS	1	1
8031	Giant cell carcinoma	1	1
8032	Spindle cell carcinoma, NOS	14	11
8051	Verrucous carcinoma, NOS	2	1
8070	Squamous cell carcinoma, NOS	195	80
8071	Squamous cell carcinoma, keratinizing, NOS	8	4

Table 22 continued...

ICD 10 code and histology	Male	Female
8072 Squamous cell carcinoma, large cell, nonkeratinizing	0	1
8075 Squamous cell carcinoma, adenoid	1	1
8082 Lymphoepithelial carcinoma	1	0
8083 Basaloid squamous cell carcinoma	4	1
8090 Basal cell carcinoma, NOS	44	44
8091 Multifocal superficial basal cell carcinoma	0	1
8092 Infiltrating basal cell carcinoma, NOS	3	1
8093 Basal cell carcinoma, fibroepithelial	0	1
8094 Basosquamous carcinoma	0	4
8097 Basal cell carcinoma, nodular	4	7
8110 Pilomatrix carcinoma	1	1
8140 Adenocarcinoma, NOS	3	6
8200 Adenoid cystic carcinoma	0	2
8310 Clear cell adenocarcinoma, NOS	0	1
8320 Granular cell carcinoma	0	1
8390 Skin appendage carcinoma	1	0
8401 Apocrine adenocarcinoma	1	0
8402 Nodular hidradenoma, malignant	0	2
8409 Eccrine poroma, malignant	1	0
8410 Sebaceous adenocarcinoma	7	4
8440 Cystadenocarcinoma, NOS	0	1
8480 Mucinous adenocarcinoma	2	1
8542 Paget disease, extramammary (except Paget disease)	2	0
8562 Epithelial-myoepithelial carcinoma	1	0
8720 Malignant melanoma, NOS (except juvenile melanoma)	49	43
8721 Nodular melanoma	8	3
8723 Malignant melanoma, regressing	3	1
8730 Amelanotic melanoma	0	1
8740 Malignant melanoma in junctional nevus	0	1
8742 Lentigo maligna melanoma	0	1
8744 Acral lentiginous melanoma, malignant	1	4
8746 Mucosal lentiginous melanoma	1	0
8772 Spindle cell melanoma, NOS	1	1
8832 Dermatofibrosarcoma, NOS	3	7
8833 Pigmented dermatofibrosarcoma protuberans	1	2
Total	389	264




Figure 35: Age Specific Incidence Rates of Skin cancer in Sri Lanka, 2021




Figure 36: Age Standardized Incidence Rates of Skin cancer in Sri Lanka, 2005 - 2021

Table 23: Breast cancer incidence data in Sri Lanka,2021

Group	Number	%	ASR	Cum. Rate
Male	124	0.7	1.1	0.13
Female	5485	27.5	40.5	4.83

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site		Male	Female
C500	Nipple and areola	1	41
C501	Central portion of breast	3	79
C502	Upper-inner quadrant of breast	0	123
C503	Lower-inner quadrant of breast	1	54
C504	Upper-outer quadrant of breast	6	353
C505	Lower-outer quadrant of breast	4	107
C506	Axillary tail of breast	2	42
C508	Overlapping lesion of breast	7	94
C509	Breast, unspecified	100	4592
Total		124	5485

ICD 10 code and histology		Male	Female
8000	Neoplasm, malignant	10	388
8001	Tumour cells, malignant	0	3
8002	Malignant tumor, small cell type	0	1
8004	Malignant tumor, spindle cell type	0	1
8005	Malignant tumor, clear cell type	0	1
8010	Carcinoma, NOS	49	2576
8011	Epithelioma, malignant	0	1
8020	Carcinoma, undifferentiated, NOS	0	1
8022	Pleomorphic carcinoma	0	2
8030	Giant cell and spindle cell carcinoma	0	1
8032	Spindle cell carcinoma, NOS	0	4
8050	Papillary carcinoma, NOS	1	47
8051	Verrucous carcinoma, NOS	0	1
8070	Squamous cell carcinoma, NOS	5	29
8072	Squamous cell carcinoma, large cell, nonkeratizing	0	1
8076	Squamous cell carcinoma, microinvasive	1	24

Table 23 continued...

ICD 10 code and histology		Male	Female
8140	Adenocarcinoma, NOS	5	63
8200	Adenoid cystic carcinoma	0	2
8201	Cribriform carcinoma, NOS	0	3
8211	Tubular adenocarcinoma	0	2
8260	Papillary adenocarcinoma, NOS	2	14
8480	Mucinous adenocarcinoma	4	63
8500	Infiltrating duct carcinoma, NOS	28	1849
8502	Secretory carcinoma of breast	0	2
8503	Intraductal papillary adenocarcinoma with invasive	2	20
8504	Intracystic carcinoma, NOS	0	1
8510	Medullary carcinoma, NOS	0	11
8513	Atypical medullary carcinoma	1	0
8514	Duct carcinoma, desmoplastic type	10	117
8520	Lobular carcinoma, NOS	0	110
8521	Infiltrating ductular carcinoma	2	59
8522	Infiltrating duct and lobular carcinoma	0	13
8523	Infiltrating duct mixed with other types of carcinoma	1	10
8524	Infiltrating lobular mixed with other types of carcinoma	0	3
8530	Inflammatory carcinoma	0	2
8540	Paget disease, mammary	0	7
8543	Paget disease and intraductal carcinoma of breast	0	4
8560	Adenosquamous carcinoma	0	1
8572	Adenocarcinoma with spindle cell metaplasia	0	1
8575	Metaplastic carcinoma, NOS	1	15
8800	Sarcoma, NOS	0	1
8801	Spindle cell sarcoma	0	2
8810	Fibrosarcoma, NOS	0	1
8850	Liposarcoma, NOS	0	1
8890	Leiomyosarcoma, NOS	2	0
8895	Myosarcoma	0	1
8940	Mixed tumour, malignant, NOS	0	1
8980	Carcinosarcoma, NOS	0	3
9020	Phyllodes tumour, malignant	0	21
9120	Hemangiosarcoma	0	1
Total		124	5485




Figure 37: Age Specific Incidence Rates of Breast cancer, 2021




Figure 38: Age Standardized Incidence Rates of Breast cancer in Sri Lanka, 2005-2021

Table 24: Cervix Uteri cancer incidence data in Sri Lanka, 2021

Group	Number	%	ASR	Cum. Rate
Female	1238	6.2	9.1	1.13

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site		Female
C530	Endocervix	56
C531	Exocervix	31
C538	Overlapping lesion of cervix uteri	30
C539	Cervix uteri, unspecified	1121
Total		1238

ICD 10 code and histology		Female
8000	Neoplasm, malignant	53
8005	Malignant tumor, clear cell type	1
8010	Carcinoma, NOS	167
8032	Spindle cell carcinoma, NOS	5
8050	Papillary carcinoma, NOS	1
8052	Papillary squamous cell carcinoma	1
8070	Squamous cell carcinoma, NOS	612
8071	Squamous cell carcinoma, keratinizing, NOS	124
8072	Squamous cell carcinoma, large cell, nonkeratinizing	106
8073	Squamous cell carcinoma, small cell, nonkeratinizing	9
8076	Squamous cell carcinoma, microinvasive	2
8083	Basaloid squamous cell carcinoma	4
8098	Adenoid basal carcinoma	4
8140	Adenocarcinoma, NOS	98
8141	Scirrhus adenocarcinoma	1
8260	Papillary adenocarcinoma, NOS	2
8262	Villous adenocarcinoma	1
8310	Clear cell adenocarcinoma, NOS	1
8380	Endometrioid adenocarcinoma, NOS	27
8384	Adenocarcinoma, endocervical type	3
8480	Mucinous adenocarcinoma	4
8560	Adenosquamous carcinoma	5
8574	Adenocarcinoma with neuroendocrine differentiation	1
8800	Sarcoma, NOS	2
8810	Fibrosarcoma, NOS	1
8933	Adenosarcoma	1
8980	Carcinosarcoma, NOS	2
Total		1238




Figure 39: Age Specific Incidence Rates of Cervical cancer in Sri Lanka, 2021




Figure 40: Age Standardized Incidence Rates of Cervical cancer in Sri Lanka, 2005-2021

Table 25: Uterine cancer incidence data in Sri Lanka, 2021

Group	Number	%	ASR	Cum.Rate
Female	1228	6.1	9.0	1.20

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site		Female
C540	Isthmus uteri	6
C541	Endometrium	833
C542	Myometrium	9
C543	Fundus uteri	1
C548	Overlapping lesion of corpus uteri	1
C549	Corpus uteri, unspecified	29
C55	Uterus, part unspecified	349
Total		1228

ICD 10 code and histology		Female
8000	Neoplasm, malignant	74
8005	Malignant tumor, clear cell type	1
8010	Carcinoma, NOS	110
8032	Spindle cell carcinoma, NOS	1
8050	Papillary carcinoma, NOS	2
8070	Squamous cell carcinoma, NOS	34
8071	Squamous cell carcinoma, keratinizing, NOS	9
8072	Squamous cell carcinoma, large cell, nonkeratinizing	5
8083	Basaloid squamous cell carcinoma	1
8140	Adenocarcinoma, NOS	175
8141	Scirrhous adenocarcinoma	1
8147	Basal cell adenocarcinoma	1
8246	Neuroendocrine carcinoma, NOS	1
8260	Papillary adenocarcinoma, NOS	7
8310	Clear cell adenocarcinoma, NOS	14
8380	Endometrioid adenocarcinoma, NOS	677
8381	Endometrioid adenofibroma, malignant	1
8382	Endometrioid adenocarcinoma, secretory variant	2
8383	Endometrioid adenocarcinoma, ciliated cell variant	1
8384	Adenocarcinoma, endocervical type	1
8480	Mucinous adenocarcinoma	2

Table 25 continued...

ICD 10 code and histology		Female
8560	Adenosquamous carcinoma	2
8562	Epithelial-myoeplithelial carcinoma	1
8575	Metaplastic carcinoma, NOS	1
8800	Sarcoma, NOS	7
8890	Leiomyosarcoma, NOS	31
8891	Epithelioid leiomyosarcoma	1
8896	Myxoid leiomyosarcoma	1
8930	Endometrial stromal sarcoma, NOS	7
8931	Endometrial stromal sarcoma, low grade	1
8933	Adenosarcoma	2
8935	Stromal sarcoma, NOS	5
8940	Mixed tumor, malignant, NOS	2
8950	Mullerian mixed tumour	17
8980	Carcinosarcoma, NOS	30
Total		1228




Figure 41: Age Specific Incidence Rates of Uterine cancer in Sri Lanka, 2021




Figure 42: Age Standardized Incidence Rates of Uterine cancer in Sri Lanka, 2006-2021

Table 26: Ovary cancer incidence in Sri Lanka, 2021

Group	Number	%	ASR	Cum. Rate
Female	1308	6.6	9.9	1.17

ASR - Age Standardised Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site		Female
C569	Ovary	1308
Total		1308

ICD 10 code and histology		Female
8000	Neoplasm, malignant	110
8001	Tumour cells, malignant	3
8005	Malignant tumor, clear cell type	20
8010	Carcinoma, NOS	201
8032	Spindle cell carcinoma, NOS	2
8050	Papillary carcinoma, NOS	14
8070	Squamous cell carcinoma, NOS	12
8071	Squamous cell carcinoma, keratinizing, NOS	1
8120	Transitional cell carcinoma, NOS	1
8140	Adenocarcinoma, NOS	118
8141	Scirrhus adenocarcinoma	1
8147	Basal cell adenocarcinoma	1
8240	Carcinoid tumor, NOS	1
8246	Neuroendocrine carcinoma, NOS	3
8260	Papillary adenocarcinoma, NOS	36
8262	Villous adenocarcinoma	1
8310	Clear cell adenocarcinoma, NOS	16
8313	Clear cell adenocarcinofibroma	1
8320	Granular cell carcinoma	5
8380	Endometrioid adenocarcinoma, NOS	82
8440	Cystadenocarcinoma, NOS	2
8441	Serous cystadenocarcinoma, NOS	334
8450	Papillary cystadenocarcinoma, NOS	9
8460	Papillary serous cystadenocarcinoma	67
8461	Serous surface papillary carcinoma	10
8470	Mucinous cystadenocarcinoma, NOS	51
8471	Papillary mucinous cystadenocarcinoma	1

Table 26 continued...

ICD 10 code and histology		Female
8480	Mucinous adenocarcinoma	48
8490	Signet ring cell carcinoma	2
8560	Adenosquamous carcinoma	2
8570	Adenocarcinoma with squamous metaplasia	1
8620	Granulosa cell tumour, malignant	38
8631	Sertoli-Leydig cell tumour, poorly differentiate	3
8640	Sertoli cell carcinoma	1
8670	Steroid cell tumour, malignant	1
8800	Sarcoma, NOS	1
8801	Spindle cell sarcoma	1
8803	Small cell sarcoma	1
8810	Fibrosarcoma, NOS	3
8935	Stromal sarcoma, NOS	3
8950	Mullerian mixed tumour	6
8980	Carcinosarcoma, NOS	5
8991	Embryonal sarcoma	1
9000	Brenner tumour, malignant	1
9014	Serous adenocarcinofibroma	7
9060	Dysgerminoma	25
9064	Germinoma	3
9065	Germ cell tumour, nonseminomatous	2
9071	Yolk sac tumour	13
9080	Teratoma, malignant, NOS	26
9085	Mixed germ cell tumour	10
9090	Struma ovarii, malignant	1
Total		1308




Figure 43: Age Specific Incidence Rates of Ovarian cancer in Sri Lanka, 2021




Figure 44: Age Standardized Incidence Rates of Ovarian cancer in Sri Lanka, 2005-2021

Table 27: Prostate cancer incidence data in Sri Lanka, 2021

Group	Number	%	ASR	Cum. Rate
Male	1286	7.5	11.6	1.58

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site		Male
C619	Prostate Gland	1286
Total		1286

ICD 10 code and histology		Male
8000	Neoplasm, malignant	106
8002	Malignant tumour, small cell type	1
8010	Carcinoma, NOS	171
8070	Squamous cell carcinoma, NOS	7
8083	Basaloid squamous cell carcinoma	1
8120	Transitional cell carcinoma, NOS	14
8130	Papillary transitional cell carcinoma	3
8140	Adenocarcinoma, NOS	591
8246	Neuroendocrine carcinoma, NOS	2
8500	Infiltrating duct carcinoma, NOS	4
8503	Intraductal papillary adenocarcinoma	1
8550	Acinar cell carcinoma	354
8551	Acinar cell cystadenocarcinoma	29
8560	Adenosquamous carcinoma	2
Total		1286




Figure 45: Age Specific Incidence Rates of Prostate cancer in Sri Lanka, 2021




Figure 46: Age Standardized Incidence Rates of Prostate cancer in Sri Lanka, 2005- 2021

Table 28 : Urinary bladder cancer incidence data in Sri Lanka, 2021

Group	Number	%	ASR	Cum. Rate
Male	731	4.2	6.5	0.87
Female	185	0.9	1.3	0.19

ASR - Age Standardized Incidence Rate per 100,000 population
 Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site		Male	Female
C670	Trigone of bladder	6	1
C671	Dome of bladder	2	1
C672	Lateral wall of bladder	6	0
C673	Anterior wall of bladder	4	1
C674	Posterior wall of bladder	5	4
C675	Bladder neck	15	1
C676	Ureteric orifice	1	0
C677	Urachus	2	0
C678	Overlapping lesion of bladder	9	2
C679	Bladder, unspecified	681	175
Total		731	185

ICD 10 code and histology		Male	Female
8000	Neoplasm, malignant	42	8
8001	Tumor cells, malignant	2	0
8010	Carcinoma, NOS	57	14
8020	Carcinoma, undifferentiated, NOS	1	0
8030	Giant cell and spindle cell carcinoma	1	0
8032	Spindle cell carcinoma, NOS	1	2
8050	Papillary carcinoma, NOS	11	5
8052	Papillary squamous cell carcinoma	1	0
8070	Squamous cell carcinoma, NOS	15	17
8120	Transitional cell carcinoma, NOS	392	87
8122	Transitional cell carcinoma, spindle cell	2	0
8130	Papillary transitional cell carcinoma	168	43
8131	Transitional cell carcinoma, micropapillary	3	1
8140	Adenocarcinoma, NOS	18	4
8201	Cribriform carcinoma, NOS	1	0
8260	Papillary adenocarcinoma, NOS	5	0
8310	Clear cell adenocarcinoma, NOS	1	0
8480	Mucinous adenocarcinoma	2	2
8490	Signet ring cell carcinoma	2	0

Table 28 continued...

ICD 10 code and histology		Male	Female
8550	Acinar cell carcinoma	5	0
8680	Paraganglioma, malignant	0	1
8900	Rhabdomyosarcoma, NOS	1	0
8990	Mesenchymoma, malignant	0	1
Total		731	185




Figure 47: Age Specific Incidence Rates of Urinary bladder cancer in Sri Lanka, 2021




Figure 48: Age Standardized Incidence Rates of Urinary bladder cancer in Sri Lanka, 2005-2021

Table 29: Thyroid gland cancer incidence data in Sri Lanka, 2021

Group	Number	%	ASR	Cum. Rate
Male	554	3.2	4.8	0.53
Female	2043	10.2	15.9	1.49

ASR - Age Standardized Incidence Rate per 100,000 population
Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site		Male	Female
C739	Thyroid Gland	554	2043
Total		554	2043

ICD 10 code and histology		Male	Female
8000	Neoplasm, malignant	18	53
8010	Carcinoma, NOS	60	153
8021	Carcinoma, anaplastic, NOS	9	17
8022	Pleomorphic carcinoma	0	1
8030	Giant cell and spindle cell carcinoma	0	1
8050	Papillary carcinoma, NOS	155	601
8052	Papillary squamous cell carcinoma	0	1
8070	Squamous cell carcinoma, NOS	8	12
8071	Squamous cell carcinoma, keratinizing, NOS	1	0
8140	Adenocarcinoma, NOS	8	6
8190	Trabecular adenocarcinoma	0	1
8200	Adenoid cystic carcinoma	0	1
8246	Neuroendocrine carcinoma, NOS	0	1
8260	Papillary adenocarcinoma, NOS	148	469
8290	Oxyphilic adenocarcinoma	2	15
8330	Follicular adenocarcinoma, NOS	25	126
8331	Follicular adenocarcinoma, well differentiated	0	1
8335	Follicular carcinoma, minimally invasive	33	143
8337	Insular carcinoma	0	3
8340	Papillary carcinoma, follicular variant	24	106
8341	Papillary microcarcinoma	54	301
8343	Papillary carcinoma, encapsulated	0	11
8344	Papillary carcinoma, columnar cell	1	0
8345	Medullary carcinoma with amyloid stroma	1	1
8346	Mixed medullary-follicular carcinoma	0	1
8347	Mixed medullary-papillary carcinoma	0	2
8350	Nonencapsulated sclerosing carcinoma	1	6
8430	Mucoepidermoid carcinoma	1	0
8510	Medullary carcinoma, NOS	4	9
8631	Sertoli-Leydig cell tumour, poorly differentiate	0	1
8852	Myxoid liposarcoma	1	0
Total		554	2043




Figure 49: Age Specific Incidence Rates of Thyroid cancer in Sri Lanka, 2021




Figure 50: Age Standardized Incidence Rates of Thyroid cancer in Sri Lanka, 2005-2021

Table 30: Lymphoma incidence data in Sri Lanka, 2021

Group	Number	%	ASR	Cum. Rate
Male	842	4.9	7.5	0.82
Female	619	3.1	4.8	0.50

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site		Male	Female
C810	Nodular lymphocyte predominant Hodgkin lymphoma	1	1
C811	Nodular sclerosis (classical) Hodgkin lymphoma	23	14
C812	Mixed cellularity (classical) Hodgkin lymphoma	8	2
C813	Lymphocyte depleted (classical) Hodgkin lymphoma	3	0
C814	Lymphocyte-rich (classical) Hodgkin lymphoma	7	4
C819	Hodgkin lymphoma, unspecified	134	118
C820	Follicular lymphoma grade I	6	1
C821	Follicular lymphoma grade II	4	4
C822	Follicular lymphoma grade III, unspecified	1	3
C829	Follicular lymphoma, unspecified	35	40
C830	Small cell B-cell lymphoma	22	13
C831	Mantle cell lymphoma	15	5
C833	Diffuse large B-cell lymphoma	51	45
C835	Lymphoblastic (diffuse) lymphoma	57	37
C837	Burkitt lymphoma	10	1
C838	Other non-follicular lymphoma	0	1
C840	Mycosis fungoides	7	16
C844	Peripheral T-cell lymphoma, not elsewhere classified	14	3
C846	Anaplastic large cell lymphoma, ALK-positive	10	8
C848	Cutaneous T-cell lymphoma, unspecified	2	0
C857	Other specified types of non-Hodgkin lymphoma	9	14
C859	Non-Hodgkin's lymphoma, unspecified	406	280
C964	Sarcoma of dendritic cells (accessory cells)	0	1
C966	Unifocal Langerhans-cell histiocytosis	17	7
C968	Histiocytic sarcoma	0	1
Total		842	619

ICD 10 code and histology		Male	Female
9590	Malignant lymphoma, NOS	120	72
9591	Malignant lymphoma, non-Hodgkin, NOS	286	208
9596	Composite Hodgkin and non-Hodgkin lymphoma	9	14
9650	Hodgkin lymphoma, NOS	134	118
9651	Hodgkin lymphoma, lymphocyte-rich	7	4
9652	Hodgkin lymphoma, mixed cellularity, NOS	8	2
9653	Hodgkin lymphoma, lymphocyte depletion, NOS	1	0
9659	Hodgkin lymphoma, nodular lymphocyte predominant	1	1
9662	Hodgkin sarcoma	2	0
9663	Hodgkin lymphoma, nodular sclerosis, NOS	21	14
9665	Hodgkin lymphoma, nodular sclerosis, grade 1	1	0
9667	Hodgkin lymphoma, nodular sclerosis, grade 2	1	0
9670	Malignant lymphoma, small B lymphocytic, NOS	12	11
9671	Malignant lymphoma, lymphoplasmacytic	7	1
9673	Mantle cell lymphoma	15	5
9678	Primary effusion lymphoma	0	1
9680	Malignant lymphoma, large B-cell, diffuse, NOS	49	41
9684	Malignant lymphoma, large B-cell, diffuse, immunoblastic	2	4
9687	Burkitt lymphoma, NOS	10	1
9689	Splenic marginal zone B-cell lymphoma	3	1
9690	Follicular lymphoma, NOS	35	40
9691	Follicular lymphoma, grade 2	4	4
9695	Follicular lymphoma, grade 1	6	1
9698	Follicular lymphoma, grade 3	1	3
9700	Mycosis fungoides	7	16
9702	Mature T-cell lymphoma, NOS	14	3
9709	Cutaneous T-cell lymphoma, NOS	2	0
9714	Anaplastic large cell lymphoma, T cell and	10	8
9727	Precursor cell lymphoblastic lymphoma, NOS	10	6
9728	Precursor B-cell lymphoblastic lymphoma	15	20
9729	Precursor T-cell lymphoblastic lymphoma	32	11
9751	Langerhans cell histiocytosis, NOS	17	2
9755	Histiocytic sarcoma	0	1
9758	Follicular dendritic cell sarcoma	0	1
Total		842	619




Figure 51: Age Specific Incidence Rates of Lymphoma in Sri Lanka 2021




Figure 52: Age Standardized Incidence Rates of Lymphoma in Sri Lanka 2021

Table 31: Leukaemia incidence data in Sri Lanka, 2021

Group	Number	%	ASR	Cum. Rate
Male	554	3.4	5.7	0.49
Female	2043	2.4	4.0	0.38

ASR - Age Standardized Incidence Rate per 100,000 population

Cum. Rate - Cumulative Rate (0-74 years) per 100,000 population

ICD 10 code and site		Male	Female
C910	Acute lymphoblastic leukaemia [ALL]	208	129
C911	Chronic lymphocytic leukaemia of B-cell type	15	15
C914	Hairy-cell leukaemia	5	1
C918	Mature B-cell leukaemia Burkitt-type	2	4
C919	Lymphoid leukaemia, unspecified	3	5
C920	Acute myeloblastic leukaemia [AML]	161	175
C921	Chronic myeloid leukaemia [CML], BCR/ABL-positive	80	50
C924	Acute promyelocytic leukaemia [PML]	5	9
C925	Acute myelomonocytic leukaemia	1	3
C926	Acute myeloid leukaemia with 11q23-abnormality	1	0
C929	Myeloid leukaemia, unspecified	13	13
C930	Acute monoblastic/monocytic leukaemia	7	3
C931	Chronic myelomonocytic leukaemia	4	6
C933	Juvenile myelomonocytic leukaemia	1	1
C940	Acute erythroid leukaemia	15	9
C942	Acute megakaryoblastic leukaemia	1	1
C944	Acute panmyelosis with myelofibrosis	5	5
C947	Other specified leukaemias	1	0
C950	Acute leukaemia of unspecified cell type	58	29
C959	Leukaemia, unspecified	16	11
Total		602	469

ICD 10 code and histology		Male	Female
9800	Leukaemia, NOS	16	11
9801	Acute Leukaemia, NOS	58	29
9820	Lymphoid Leukaemia, NOS	3	5
9823	B-cell chronic lymphocytic leukemia/small lymphoma	15	15
9826	Burkitt cell Leukaemia	2	4

Table 31 continued...

ICD 10 code and histology		Male	Female
9835	Precursor cell lymphoblastic leukaemia, NOS	20	15
9836	Precursor B-cell lymphoblastic leukaemia	130	93
9837	Precursor T-cell lymphoblastic leukaemia	58	21
9840	Acute myeloid leukaemia, M6 type	15	9
9860	Myeloid leukaemia, NOS	13	13
9861	Acute myeloid leukaemia, NOS	150	165
9863	Chronic myeloid leukaemia, NOS	78	48
9866	Acute promyelocytic leukaemia, t(15;17)(q22;q 11)	5	9
9867	Acute myelomonocytic leukaemia	1	3
9870	Acute basophilic leukaemia	1	0
9872	Acute myeloid leukaemia, minimal differentiation	1	1
9873	Acute myeloid leukaemia without maturation	2	4
9874	Acute myeloid leukaemia with maturation	8	5
9875	Chronic myelogenous leukaemia, BCR/ABL	2	2
9891	Acute monocytic leukaemia	7	3
9897	Acute myeloid leukaemia, 11q23 abnormalities	1	0
9910	Acute megakaryoblastic leukaemia	1	1
9931	Acute panmyelosis with myelofibrosis	5	5
9940	Hairy cell leukaemia	5	1
9945	Chronic myelomonocytic leukaemia, NOS	4	6
9946	Juvenile myelomonocytic leukaemia	1	1
Total		602	469



Figure 53: Age Specific Incidence Rates of Leukaemia in Sri Lanka, 2021




Figure 54: Age Standardized Incidence Rates of Leukaemia in Sri Lanka, 2011– 2021

Clinical Staging at the point of diagnosis - 2021




Figure 55: Clinical staging at the point of diagnosis of breast cancer




Figure 56: Clinical staging at the point of diagnosis of cervical cancer




Figure 57: Clinical staging at the point of diagnosis of lip, tongue and mouth cancer

Table 32: Basis of diagnosis of cancer patients in Sri Lanka, 2021

Basis of diagnosis	Frequency	Percentage
Diagnosed microscopically		
Histology of primary	34193	90.6
Histology of metastasis	1975	5.2
Cytology/Haematology only	334	0.9
Subtotal	36502	96.7
Diagnosed non-microscopically		
Clinical investigation including X ray, USS, CT, etc. (imaging only)	201	0.5
Death certificate only	898	2.4
Clinical only	8	0
Specific biochemical/immunological test only	12	0
Exploratory surgery	4	0
Subtotal	1123	3.0
Unknown/Not recorded	128	0.3
Total	37753	100




Figure 58: Basis of diagnosis of cancer in Sri Lanka, 2021







Figure 59: Percentage of newly detected cancer patients who received different types of treatment in Sri Lanka, 2021

Table 33: Childhood and adolescent cancer incidence data (0 - 19 years) in Sri Lanka, 2021

According to International Classification of Childhood Cancer third edition (ICCC -3) by sex

ICCC-3 Site Group		ICD-O-3 Histology	Male	Female	Total		
I Leukaemias, myeloproliferative diseases and myelodysplastic diseases	a	Lymphoid leukaemia	9826	Brukitt cell leukaemia	2	3	5
			9835	Precursor cell lymphoblastic leukaemia, NOS	10	6	16
			9836	Precursor B-cell lymphoblastic leukaemia	107	76	183
			9837	Precursor T-cell lymphoblastic leukaemia	37	15	52
	b	Acute myeloid leukaemia	9861	Acute myeloid leukaemia, NOS	23	13	36
			9867	Acute myelomonocytic leukaemia	0	1	1
			9873	Acute myeloid leukaemia, without maturation	0	1	1
			9874	Acute myeloid leukaemia, with maturation	0	1	1
			9891	Acute monocytic leukaemia	3	0	3
			9910	Acute megakaryoblastic leukaemia	1	0	1
			9863	Chronic myeloid leukaemia, NOS	2	4	6
	c	Chronic myeloproliferative diseases					
	d	Myelodysplastic syndrome and other myeloproliferative diseases	9946	Juvenile myelomonocytic leukaemia	1	1	2
	e	Unspecified and other specified leukaemia	9800	leukaemia, NOS	3	2	5
			9801	Acute leukaemia, NOS	19	10	29
Total			208	133	341		
II Lymphomas and reticuloendothelial neoplasms	a	Hodgkin lymphomas	9650	Hodgkin lymphoma, NOS	23	16	39
			9651	Hodgkin lymphoma, Lymphocyte-rich	1	0	1
			9663	Hodgkin lymphoma, nodular sclerosis, NOS	2	0	2
	b	Non-Hodgkin lymphomas (except Burkitt lymphoma)	9591	Malignant lymphoma, non-Hodgkin, NOS	6	8	14

ICCC-3 Site Group			ICD-O-3 Histology	Male	Female	Total
			9670 Malignant lymphoma, small B lymphocytic, NOS	1	2	3
			9680 Malignant lymphoma, large B-cell, diffuse, NOS	2	1	3
			9700 Mycosis fungoides	3	2	5
			9714 Anaplastic large cell lymphoma, T cell and Null Cell type	2	3	5
			9727 Precursor cell lymphoblastic lymphoma, NOS	4	1	5
			9728 Precursor B-cell lymphoblastic lymphoma	7	4	11
			9729 Precursor T-cell lymphoblastic lymphoma	14	2	16
	c	Burkitt lymphoma	9687 Burkitt lymphoma, NOS	10	1	11
	d	Miscellaneous lymphoreticular neoplasms	9752 Langerhans cell histiocytosis, unifocal	0	2	2
			9753 Langerhans cell histiocytosis, multifocal	1	2	3
			9754 Langerhans cell histiocytosis, disseminated	15	3	18
			9755 Histiocytic sarcoma	0	1	1
	e	Unspecified lymphomas	9590 Malignant Lymphoma, NOS	4	2	6
			9596 Composite Hodgkin and non-Hodgkin lymphoma	2	1	3
Total				97	51	148
III CNS and miscellaneous intracranial and intraspinal neoplasms	a	Ependymomas and choroid plexus tumour	9391 Ependymoma, NOS	4	4	8
			9392 Ependymoma, anaplastic	5	4	9
	b	Astrocytoma	9380 Glioma, malignant	2	4	6
			9400 Astrocytoma, NOS	3	4	7
			9401 Astrocytoma, anaplastic	0	1	1
			9410 Protoplasmic astrocytoma	1	0	1
			9421 Pilocytic astrocytoma	2	1	3

ICCC-3 Site Group		ICD-O-3 Histology		Male	Female	Total	
		9440	Glioblastoma, NOS	3	1	4	
c	Intracranial and intraspinal embryonal tumours	9470	Medulloblastoma, NOS	12	11	23	
		9473	Primitive neuroectodermal tumour, NOS	2	1	3	
		9508	Atypical teratoid/rhabdoid tumour	0	1	1	
d	Other gliomas	9380	Glioma, malignant	13	9	22	
		9450	Oligodendroglioma, NOS	1	2	3	
e	Other specified intracranial and intraspinal neoplasms	9362	Pineoblastoma	3	1	4	
		9505	Ganglioglioma, anaplastic	0	1	1	
f	Unspecified intracranial and intraspinal neoplasms	8000	Neoplasm, malignant	1	1	2	
Total				52	46	98	
IV Neuroblastoma and other peripheral nervous cell	a	Neuroblastoma and ganglioneuroblastoma	9490	Ganglioneuroblastoma	2	5	7
			9500	Neuroblastoma, NOS	14	15	29
	b	Other peripheral nervous cell tumour	9522	Olfactory neuroblastoma	1	0	1
Total				17	20	37	
V Retinoblastoma		Retinoblastoma	9510	Retinoblastoma, NOS	17	10	27
Total				17	10	27	
VI Renal tumours	a	Nephroblastoma and other nonepithelial renal tumours	8960	Nephroblastoma, NOS	25	13	38
Total				25	13	38	
VII Hepatic tumours	a	Hepatoblastoma	8970	Hepatoblastoma	7	10	17
	b	Hepatic carcinomas	8170	Hepatocellular carcinoma, NOS	0	2	2
	c	unspecified malignant hepatic tumors	8000	Neoplasm, malignant	1	0	1

ICCC-3 Site Group		ICD-O-3 Histology		Male	Female	Total	
Total				8	12	20	
VIII Malignant bone tumours	a	Osteosarcomas	9180	Osteosarcoma, NOS	26	14	40
			9181	Chondroblastic osteosarcoma	3	2	5
			9200	Osteoclastoma, NOS	1	0	1
	c	Ewing tumours and related sarcomas of bone	9260	Ewing sarcoma	22	18	40
	d	Other specified malignant bone tumours	9250	Giant cell tumour of bone, malignant	2	2	4
			9261	Adamantinoma of long bones	1	0	1
			9370	Chordoma, NOS	0	1	1
Total				55	37	92	
IX Soft tissue and other extraosseous sarcoma	a	Rhabdomyosarcoma	8900	Rhabdomyosarcoma, NOS	8	3	11
			8910	Embryonal rhabdomyosarcoma, NOS	2	2	4
			8920	Alveolar rhabdomyosarcoma	1	0	1
	d	Other specified soft tissue sarcomas	8806	Desmoplastic small round cell tumour	3	4	7
			8963	Malignant rhabdoid tumour	0	1	1
			8982	Malignant myoepithelioma	0	1	1
			9040	Synovial sarcoma, NOS	4	1	5
			9041	Synovial sarcoma, spindle cell	0	1	1
			9044	Clear cell sarcoma, NOS	0	1	1
			9260	Ewing sarcoma	1	1	2
			9581	Alveolar soft part sarcoma	1	0	1
	e	Unspecified soft tissue sarcomas	8800	Sarcoma, NOS	3	0	3
			8801	Spindle cell sarcoma	1	1	2
			8803	Small cell sarcoma	1	0	1
			8804	Epithelioid sarcoma	2	0	2
Total				27	16	43	

ICCC-3 Site Group		ICD-O-3 Histology		Male	Female	Total	
X Germ cell tumours, trophoblastic tumours, and neoplasms of gonads	a	Intracranial and intraspinal germ cell tumours	9064	Germinoma	1	0	1
			9085	Mixed germ cell tumor	2	0	2
	b	Malignant extracranial and extragonadal germ cell tumours	9060	Dysgerminoma	0	1	1
			9064	Germinoma	1	3	4
			9065	Germ cell tumour, nonseminomatous	1	0	1
			9071	Yolk sac tumour	0	2	2
			9080	Teratoma, malignant, NOS	1	2	3
			9085	Mixed germ cell tumour	1	1	2
	c	Malignant gonadal germ cell tumours	9060	Dysgerminoma	0	7	7
			9061	Seminoma, NOS	1	0	1
			9064	Germinoma	3	3	6
			9065	Germ cell tumour, nonseminomatous	1	0	1
			9070	Embryonal carcinoma, NOS	1	0	1
			9071	Yolk sac tumour	6	6	12
			9080	Teratoma, malignant, NOS	1	6	7
			9085	Mixed germ cell tumour	4	6	10
	d	Gonadal carcinomas	8441	Serous cystadenocarcinoma, NOS	0	1	1
			8470	Mucinous cystadenocarcinoma, NOS	0	2	2
	e	Other and unspecified malignant gonadal tumours	8000	Neoplasm, malignant	1	1	2
			8147	Basal cell adenocarcinoma	0	1	1
8650			Leydig cell tumor, malignant	2	0	2	
Total				27	42	69	
XI Other malignant epithelial neoplasms and malignant melanomas	a	Adrenal cortical carcinoma	8370	Adrenal cortical carcinoma	5	1	6
	b	Thyroid carcinoma	8010	Carcinoma, NOS	0	1	1
			8022	Pleomorphic carcinoma	0	1	1
			8050	Papillary carcinoma, NOS	4	26	30

ICCC-3 Site Group		ICD-O-3 Histology		Male	Female	Total	
		8260	Papillary adenocarcinoma, NOS	6	16	22	
		8330	Follicular adenocarcinoma, NOS	0	3	3	
		8335	Follicular carcinoma, minimally invasive	1	7	8	
		8340	Papillary carcinoma, follicular variant	1	4	5	
		8341	Papillary microcarcinoma	1	3	4	
c	Nasopharyngeal carcinomas	8010	Carcinoma, NOS	3	1	4	
d	Malignant melanomas	8721	Nodular melanoma	0	1	1	
		8723	Malignant melanoma, regressing	1	0	1	
e	Skin carcinoma	8070	Squamous cell carcinoma, NOS	2	0	2	
		8090	Basal cell carcinoma, NOS	0	1	1	
f	Other & unspecified carcinoma	8010	Carcinoma, NOS	2	0	2	
		8032	Spindle cell carcinoma, NOS	1	0	1	
		8070	Squamous cell carcinoma, NOS	2	0	2	
		8120	Transitional cell carcinoma, NOS	1	0	1	
		8130	Papillary transitional cell carcinoma	1	0	1	
		8140	Adenocarcinoma, NOS	1	0	1	
		8200	Adenoid cystic carcinoma	1	0	1	
		8246	Neuroendocrine carcinoma, NOS	2	2	4	
		8430	Mucoepidermoid carcinoma	2	1	3	
		8452	Solid pseudopapillary carcinoma	1	3	4	
		8586	Thymic carcinoma, NOS	1	0	1	
Total				39	71	110	
XII Other and unspecified malignant neoplasms	a	Other specified malignant tumours	8936	Gastrointestinal stromal sarcoma	0	1	1
			8971	Pancreatoblastoma	1	0	1
			8973	Pleuropulmonary blastoma	0	1	1
	b	Other unspecified malignant tumours	8000	Neoplasm, malignant	4	1	5
			8003	Malignant tumor, giant cell type	1	0	1
	Total				6	3	9
All sites				578	454	1032	

Table 34: Overall Cancer Incidence by province and district in Sri Lanka, 2021

Province	District	Male		Female		Total	
		No		No		No	
Western	Not known	6358	36.2	7019	34.8	13377	35.4
		3305	18.8	4280	21.2	7585	20.1
	Colombo	1690	9.6	1996	9.9	3686	9.8
	Gampaha	1064	6.1	1472	7.3	2536	6.7
Central	Kalutara	551	3.1	812	4.0	1363	3.6
		1329	7.6	1746	8.6	3075	8.1
	Kandy	695	4.0	937	4.6	1632	4.3
	Matale	327	1.9	325	1.6	652	1.7
Southern	Nuwara Eliya	307	1.7	484	2.4	791	2.1
		1354	7.6	1490	7.4	2844	7.6
	Galle	517	2.9	612	3.0	1129	3.0
	Matara	447	2.5	455	2.3	902	2.4
Northern	Hambantota	390	2.2	423	2.1	813	2.2
		635	3.6	642	3.2	1277	3.3
	Jaffna	392	2.2	367	1.8	759	2.0
	Kilinochchi	72	0.4	56	0.3	128	0.3
	Mannar	49	0.3	56	0.3	105	0.3
	Mullaitivu	38	0.2	49	0.2	87	0.2
Eastern	Vavuniya	84	0.5	114	0.6	198	0.5
		758	4.3	875	4.3	1633	4.4
	Ampara	296	1.7	329	1.6	625	1.7
	Batticaloa	299	1.7	349	1.7	648	1.7
North Western	Trincomalee	163	0.9	197	1.0	360	1.0
		1269	7.2	1358	6.7	2627	6.9
	Kurunegala	882	5.0	909	4.5	1791	4.7
North Central	Puttlam	387	2.2	449	2.2	836	2.2
		824	4.7	806	4.0	1630	4.3
Uva	Anuradhapura	493	2.8	483	2.4	976	2.6
	Polonnaruwa	331	1.9	323	1.6	654	1.7
		603	3.4	675	3.4	1278	3.4
Sabaragamuwa	Badulla	372	2.1	417	2.1	789	2.1
	Moneragala	231	1.3	258	1.3	489	1.3
		1147	6.5	1280	6.3	2427	6.4
	Ratnapura	674	3.8	772	3.8	1446	3.8
		473	2.7	508	2.5	981	2.6
Total		17582	100	20171	100.0	37753	100.0

Table 35: Leading cancer incidence data by sex and district in Sri Lanka, 2021**Western Province****Leading cancer incidence data by sex in Colombo District, 2021**

Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Trachea, bronchus and lung (C33-C34)	178	14.6	Breast (C50)	575	45.5
Prostate (C61)	176	14.5	Uterus (C54-C55)	165	13.1
Lip, tongue and mouth (C00-C06)	172	14.1	Colon and rectum (C18-C20)	163	12.9
Colon and rectum (C18-C20)	166	13.6	Ovary (C56)	138	10.9
Liver (C22)	119	9.8	Thyroid (C73)	123	9.7
Lymphoma (C81-C85, C96)	82	6.7	Cervix uteri (C53)	104	8.2
Leukaemia (C91-C95)	79	6.5	Lymphoma (C81-C85, C96)	74	5.9
Oesophagus (C15)	78	6.4	Trachea, bronchus and lung (C33-C34)	62	4.9
Pharynx (C09-C14)	65	5.3	Leukaemia (C91-C95)	56	4.4
Bladder (C67)	51	4.2	Liver (C22)	55	4.4
Total (All cancers)	1690	138.9	Total (All cancers)	1996	158.1

Leading cancer incidence data by sex in Gampaha District, 2021

Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Lip, tongue and mouth (C00-C06)	164	13.9	Breast (C50)	526	41.8
Prostate (C61)	100	8.4	Ovary (C56)	128	10.2
Colon and rectum (C18-C20)	85	7.2	Thyroid (C73)	121	9.6
Trachea, bronchus and lung (C33-C34)	79	6.7	Colon and rectum (C18-C20)	97	7.7
Lymphoma (C81-C85, C96)	70	5.9	Uterus (C54-C55)	95	7.5
Oesophagus (C15)	65	5.5	Cervix uteri (C53)	92	7.3
Pharynx (C09-C14)	56	4.7	Leukaemia (C91-C95)	49	3.9
Liver (C22)	48	4.1	Lymphoma (C81-C85, C96)	48	3.8
Leukaemia (C91-C95)	45	3.8	Lip, tongue and mouth (C00-C06)	37	2.9
Larynx (C32)	34	2.9	Trachea, bronchus and lung (C33-C34)	36	2.9
Total (All cancers)	1064	89.9	Total (All cancers)	1472	116.9

Leading cancer incidence data by sex in Kalutara District, 2021

Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Lip, tongue and mouth (C00-C06)	94	15.0	Breast (C50)	253	37.8
Colon and rectum (C18-C20)	56	8.9	Thyroid (C73)	73	10.9
Lymphoma (C81-C85, C96)	42	6.7	Ovary (C56)	60	9.0
Prostate (C61)	39	6.2	Uterus (C54-C55)	56	8.4
Oesophagus (C15)	39	6.2	Colon and rectum (C18-C20)	54	8.1
Leukaemia (C91-C95)	38	6.1	Cervix uteri (C53)	54	8.1
Trachea, bronchus and lung (C33-C34)	30	4.8	Lymphoma (C81-C85, C96)	30	4.5
Liver (C22)	26	4.1	Oesophagus (C15)	26	3.9
Larynx (C32)	23	3.7	Trachea, bronchus and lung (C33-C34)	23	3.4
Pharynx (C09-C14)	22	3.5	Leukaemia (C91-C95)	22	3.3
Total (All cancers)	551	87.9	Total (All cancers)	812	121.4

Central Province

Leading cancer incidence data by sex in Kandy District, 2021

Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Lip, tongue and mouth (C00-C06)	80	11.2	Breast (C50)	252	32.1
Trachea, bronchus and lung (C33-C34)	71	9.9	Thyroid (C73)	95	12.1
Colon and rectum (C18-C20)	59	8.2	Colon and rectum (C18-C20)	79	10.1
Oesophagus (C15)	52	7.3	Ovary (C56)	62	7.9
Lymphoma (C81-C85, C96)	52	7.3	Oesophagus (C15)	51	6.5
Leukaemia (C91-C95)	45	6.3	Cervix uteri (C53)	51	6.5
Pharynx (C09-C14)	35	4.9	Uterus (C54-C55)	48	6.1
Multiple myeloma (C90)	34	4.8	Lip, tongue and mouth (C00-C06)	39	5.0
Prostate (C61)	31	4.3	Lymphoma (C81-C85, C96)	39	5.0
Thyroid (C73)	28	3.9	Leukaemia (C91-C95)	32	4.1
Total (All cancers)	695	97.1	Total (All cancers)	937	119.3

Leading cancer incidence data by sex in Matale District, 2021

Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Lip, tongue and mouth (C00-C06)	57	22.3	Breast (C50)	81	29.5
Trachea, bronchus and lung (C33-C34)	41	16.0	Thyroid (C73)	31	11.3
Oesophagus (C15)	32	12.5	Oesophagus (C15)	29	10.6
Colon and rectum (C18-C20)	26	10.2	Lip, tongue and mouth (C00-C06)	21	7.7
Pharynx (C09-C14)	23	9.0	Ovary (C56)	17	6.2
Larynx (C32)	17	6.7	Colon and rectum (C18-C20)	17	6.2
Lymphoma (C81-C85, C96)	15	5.9	Cervix uteri (C53)	17	6.2
Leukaemia (C91-C95)	14	5.5	Trachea, bronchus and lung (C33-C34)	12	4.4
Bladder (C67)	11	4.3	Lymphoma (C81-C85, C96)	12	4.4
Prostate (C61)	11	4.3	Leukaemia (C91-C95)	10	3.6
Total (All cancers)	327	128.0	Total (All cancers)	325	118.4

Leading cancer incidence data by sex in Nuwara Eliya District, 2021

Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Lip, tongue, and mouth (C00-C06)	57	15.3	Breast (C50)	96	23.6
Oesophagus (C15)	39	10.5	Oesophagus (C15)	79	19.4
Trachea, bronchus, and lung (C33-C34)	25	6.7	Thyroid (C73)	45	11.1
Colon and rectum (C18-C20)	22	5.9	Cervix uteri (C53)	44	10.8
Prostate (C61)	21	5.6	Lip, tongue, and mouth (C00-C06)	29	7.1
Leukaemia (C91-C95)	14	3.8	Ovary (C56)	26	6.4
Stomach (C16)	13	3.5	Uterus (C54-C55)	22	5.4
Lymphoma (C81-C85, C96)	13	3.5	Colon and rectum (C18-C20)	20	4.9
Bladder (C67)	11	2.9	Lymphoma (C81-C85, C96)	16	3.9
Pharynx (C09-C14)	9	2.4	Stomach (C16)	10	2.5
Total (All cancers)	307	82.3	Total (All cancers)	484	118.9

Southern Province

Leading cancer incidence data by sex in Galle District, 2021

Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Lip, tongue and mouth (C00-C06)	97	17.6	Breast (C50)	144	24.1
Prostate (C61)	46	8.4	Thyroid (C73)	124	20.8
Colon and rectum (C18-C20)	44	8.0	Colon and rectum (C18-C20)	54	9.1
Thyroid (C73)	44	8.0	Ovary (C56)	39	6.5
Trachea, bronchus and lung (C33-C34)	43	7.8	Cervix uteri (C53)	38	6.4
Oesophagus (C15)	40	7.3	Uterus (C54-C55)	31	5.2
Pharynx (C09-C14)	23	4.2	Lymphoma (C81-C85, C96)	20	3.4
Lymphoma (C81-C85, C96)	22	4.0	Oesophagus (C15)	19	3.2
Leukaemia (C91-C95)	19	3.5	Leukaemia (C91-C95)	18	3.0
Liver (C22)	15	2.7	Trachea, bronchus and lung (C33-C34)	15	2.5
Total (All cancers)	517	94.1	Total (All cancers)	612	102.6

Leading cancer incidence data by sex in Matara District, 2021

Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Lip, tongue, and mouth (C00-C06)	112	26.8	Breast (C50)	113	24.9
Colon and rectum (C18-C20)	54	12.9	Thyroid (C73)	66	14.5
Oesophagus (C15)	37	8.9	Colon and rectum (C18-C20)	39	8.6
Prostate (C61)	23	5.5	Ovary (C56)	39	8.6
Trachea, bronchus, and lung (C33-C34)	23	5.5	Lip, tongue, and mouth (C00-C06)	25	5.5
Pharynx (C09-C14)	19	4.5	Uterus (C54-C55)	25	5.5
Thyroid (C73)	17	4.1	Leukaemia (C91-C95)	18	4.0
Lymphoma (C81-C85, C96)	17	4.1	Cervix uteri (C53)	17	3.7
Leukaemia (C91-C95)	15	3.6	Oesophagus (C15)	16	3.5
Liver (C22)	13	3.1	Brain, nervous system (CC70-C72)	11	2.4
Total (All cancers)	447	107.0	Total (All cancers)	455	100.1

Leading cancer incidence data by sex in Hambanthota District, 2021

Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Lip, tongue, and mouth (C00-C06)	79	23.8	Breast (C50)	83	24.1
Colon and rectum (C18-C20)	32	9.6	Thyroid (C73)	77	22.4
Prostate (C61)	30	9.0	Cervix uteri (C53)	41	11.9
Oesophagus (C15)	27	8.1	Colon and rectum (C18-C20)	31	9.0
Pharynx (C09-C14)	27	8.1	Ovary (C56)	29	8.4
Lymphoma (C81-C85, C96)	25	7.5	Uterus (C54-C55)	21	6.1
Leukaemia (C91-C95)	19	5.7	Lymphoma (C81-C85, C96)	18	5.2
Trachea, bronchus, and lung (C33-C34)	19	5.7	Lip, tongue, and mouth (C00-C06)	17	4.9
Thyroid (C73)	16	4.8	Leukaemia (C91-C95)	16	4.7
Larynx (C32)	12	3.6	Trachea, bronchus and lung (C33-C34)	16	4.7
Total (All cancers)	390	117.4	Total (All cancers)	423	123.0

Northern Province

Leading cancer incidence data by sex in Jaffna District, 2021

Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Lip, tongue and mouth (C00-C06)	90	30.6	Breast (C50)	97	29.2
Oesophagus (C15)	37	12.6	Cervix uteri (C53)	33	9.9
Pharynx (C09-C14)	33	11.2	Thyroid (C73)	30	9.0
Prostate (C61)	32	10.9	Oesophagus (C15)	29	8.7
Trachea, bronchus and lung (C33-C34)	29	9.9	Colon and rectum (C18-C20)	26	7.8
Larynx (C32)	25	8.5	Ovary (C56)	23	6.9
Colon and rectum (C18-C20)	20	6.8	Uterus (C54-C55)	20	6.0
Liver (C22)	12	4.1	Lip, tongue and mouth (C00-C06)	17	5.1
Lymphoma (C81-C85, C96)	11	3.7	Trachea, bronchus and lung (C33-C34)	12	3.6
Bladder (C67)	11	3.7	Lymphoma (C81-C85, C96)	10	3.0
Total (All cancers)	392	133.3	Total (All cancers)	367	110.4

Leading cancer incidence data by sex in Kilinochchi District, 2021

Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Lip, tongue and mouth (C00-C06)	20	30.5	Breast (C50)	13	19.2
Oesophagus (C15)	6	9.2	Cervix uteri (C53)	11	16.2
Pharynx (C09-C14)	5	7.6	Oesophagus (C15)	7	10.3
Thyroid (C73)	4	6.1	Thyroid (C73)	4	5.9
Prostate (C61)	4	6.1	Ovary (C56)	4	5.9
Trachea, bronchus and lung (C33-C34)	4	6.1	Trachea, bronchus and lung (C33-C34)	3	4.4
Kidney (C64)	3	4.6	Multiple myeloma (C90)	3	4.4
Lymphoma (C81-C85, C96)	3	4.6	Uterus (C54-C55)	2	3.0
Colon and rectum (C18-C20)	2	3.1	Lymphoma (C81-C85, C96)	2	3.0
Larynx (C32)	2	3.1	Lip, tongue and mouth (C00-C06)	1	1.5
Total (All cancers)	72	110.0	Total (All cancers)	56	82.7

Leading cancer incidence data by sex in Mannar District, 2021

Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Lip, tongue and mouth (C00-C06)	11	19.2	Breast (C50)	14	24.7
Trachea, bronchus and lung (C33-C34)	5	8.7	Thyroid (C73)	13	22.9
Colon and rectum (C18-C20)	5	8.7	Ovary (C56)	7	12.4
Pharynx (C09-C14)	4	7.0	Uterus (C54-C55)	5	8.8
Leukaemia (C91-C95)	4	7.0	Cervix uteri (C53)	4	7.1
Oesophagus (C15)	3	5.2	Trachea, bronchus and lung (C33-C34)	2	3.5
Prostate (C61)	3	5.2	Multiple myeloma (C90)	2	3.5
Larynx (C32)	3	5.2	Lip, tongue and mouth (C00-C06)	1	1.8
Stomach (C16)	2	3.5	Colon and rectum (C18-C20)	1	1.8
Lymphoma (C81-C85, C96)	2	3.5	Leukaemia (C91-C95)	1	1.8
Total (All cancers)	49	85.5	Total (All cancers)	56	98.8

Leading cancer incidence data by sex in Mullaitivu District, 2021

Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Lip, tongue and mouth (C00-C06)	13	26.5	Breast (C50)	9	18.3
Oesophagus (C15)	7	14.3	Thyroid (C73)	9	18.3
Thyroid (C73)	2	4.1	Cervix uteri (C53)	5	10.1
Pharynx (C09-C14)	2	4.1	Lymphoma (C81-C85, C96)	5	10.1
Colon and rectum (C18-C20)	2	4.1	Lip, tongue and mouth (C00-C06)	4	8.1
Prostate (C61)	2	4.1	Colon and rectum (C18-C20)	4	8.1
Larynx (C32)	2	4.1	Oesophagus (C15)	3	6.1
Trachea, bronchus and lung (C33-C34)	1	2.0	Brain, nervous system (CC70-C72)	2	4.1
Skin (C43-C44)	1	2.0	Ovary (C56)	1	2.0
Penis (C60)	1	2.0	Heart, mediastinum, pleura (C38)	1	2.0
Total (All cancers)	38	77.4	Total (All cancers)	49	99.4

Leading cancer incidence data by sex in Vavuniya District, 2021

Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Lip, tongue and mouth (C00-C06)	12	12.6	Breast (C50)	23	23.4
Prostate (C61)	12	12.6	Oesophagus (C15)	17	17.3
Thyroid (C73)	8	8.4	Thyroid (C73)	13	13.2
Pharynx (C09-C14)	8	8.4	Cervix uteri (C53)	10	10.2
Oesophagus (C15)	7	7.3	Ovary (C56)	9	9.1
Leukaemia (C91-C95)	6	6.3	Lip, tongue and mouth (C00-C06)	4	4.1
Colon and rectum (C18-C20)	5	5.2	Leukaemia (C91-C95)	4	4.1
Salivary gland (C07-C08)	2	2.1	Kidney (C64)	4	4.1
Lymphoma (C81-C85, C96)	2	2.1	Uterus (C54-C55)	3	3.0
Bone (C40-C41)	2	2.1	Colon and rectum (C18-C20)	3	3.0
Total (All cancers)	84	88.0	Total (All cancers)	114	115.8

Eastern Province

Leading cancer incidence data by sex in Ampara District, 2021

Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Lip, tongue and mouth (C00 -C06)	54	14.8	Breast (C50)	95	24.5
Trachea, bronchus and lung (C33 -C34)	38	10.4	Thyroid (C73)	34	8.8
Colon and rectum (C18 -C20)	25	6.9	Ovary (C56)	25	6.4
Oesophagus (C15)	18	4.9	Colon and rectum (C18-C20)	21	5.4
Bladder (C67)	17	4.7	Uterus (C54-C55)	20	5.2
Lymphoma (C81-C85, C96)	17	4.7	Lip, tongue and mouth (C00 -C06)	16	4.1
Pharynx (C09-C14)	16	4.4	Leukaemia (C91 -C95)	15	3.9
Kidney (C64)	16	4.4	Cervix uteri (C53)	14	3.6
Prostate (C61)	11	3.0	Lymphoma (C81-C85, C96)	14	3.6
Leukaemia (C91-C95)	11	3.0	Trachea, bronchus and lung (C33 -C34)	10	2.6
Total (All cancers)	296	81.3	Total (All cancers)	329	84.8

Leading cancer incidence data by sex in Batticaloa District, 2021

Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Lip, tongue, and mouth (C00-C06)	56	19.9	Breast (C50)	89	28.8
Trachea, bronchus, and lung (C33-C34)	36	12.8	Ovary (C56)	36	11.6
Pharynx (C09-C14)	24	8.5	Cervix uteri (C53)	29	9.4
Colon and rectum (C18-C20)	20	7.1	Thyroid (C73)	22	7.1
Prostate (C61)	18	6.4	Lip, tongue and mouth (C00-C06)	20	6.5
Leukaemia (C91-C95)	17	6.0	Colon and rectum (C18-C20)	20	6.5
Oesophagus (C15)	16	5.7	Oesophagus (C15)	19	6.1
Bladder (C67)	12	4.3	Uterus (C54-C55)	11	3.6
Lymphoma (C81-C85, C96)	10	3.6	Trachea, bronchus and lung (C33-C34)	9	2.9
Connective/ soft tissue (C47, C49)	8	2.8	Leukaemia (C91-C95)	9	2.9
Total (All cancers)	299	106.4	Total (All cancers)	349	112.8

Leading cancer incidence data by sex in Trincomalee District, 2021

Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Lip, tongue and mouth (C00-C06)	20	9.2	Breast (C50)	62	27.8
Trachea, bronchus and lung (C33-C34)	18	8.3	Thyroid (C73)	24	10.8
Pharynx (C09-C14)	15	6.9	Cervix uteri (C53)	22	9.9
Bladder (C67)	15	6.9	Lip, tongue and mouth (C00-C06)	20	9.0
Colon and rectum (C18-C20)	14	6.4	Colon and rectum (C18-C20)	10	4.5
Leukaemia (C91-C95)	12	5.5	Ovary (C56)	7	3.1
Lymphoma (C81-C85, C96)	11	5.1	Uterus (C54-C55)	7	3.1
Oesophagus (C15)	7	3.2	Lymphoma (C81-C85, C96)	5	2.2
Thyroid (C73)	6	2.8	Bladder (C67)	4	1.8
Prostate (C61)	6	2.8	Pancreas (C25)	3	1.3
Total (All cancers)	163	74.8	Total (All cancers)	197	88.3

Northwestern Province

Leading cancer incidence data by sex in Kurunegala District, 2021

Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Lip, tongue and mouth (C00 -C06)	177	21.2	Breast (C50)	252	27.8
Oesophagus (C15)	104	12.4	Thyroid (C73)	94	10.4
Pharynx (C09 -C14)	69	8.2	Colon and rectum (C18 -C20)	79	8.7
Colon and rectum (C18 -C20)	65	7.8	Ovary (C56)	72	7.9
Trachea, bronchus and lung (C33 -C34)	54	6.5	Cervix uteri (C53)	61	6.7
Leukaemia (C91 -C95)	52	6.2	Uterus (C54 -C55)	51	5.6
Lymphoma (C81 -C85, C96)	46	5.5	Oesophagus (C15)	41	4.5
Prostate (C61)	45	5.4	Leukaemia (C91 -C95)	33	3.6
Thyroid (C73)	38	4.5	Lip, tongue and mouth (C00 -C06)	31	3.4
Liver (C22)	30	3.6	Lymphoma (C81 -C85, C96)	28	3.1
Total (All cancers)	882	105.4	Total (All cancers)	909	100.3

Leading cancer incidence data by sex in Puttlam District, 2021

Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Lip, tongue and mouth (C00 -C06)	69	16.8	Breast (C50)	144	32.9
Pharynx (C09 -C14)	45	11.0	Thyroid (C73)	52	11.9
Trachea, bronchus and lung (C33 -C34)	29	7.1	Cervix uteri (C53)	46	10.5
Leukaemia (C91 -C95)	29	7.1	Ovary (C56)	30	6.9
Oesophagus (C15)	25	6.1	Leukaemia (C91 -C95)	23	5.3
Prostate (C61)	20	4.9	Colon and rectum (C18 -C20)	22	5.0
Lymphoma (C81 -C85, C96)	15	3.7	Uterus (C54 -C55)	14	3.2
Liver (C22)	15	3.7	Lymphoma (C81 -C85, C96)	14	3.2
Thyroid (C73)	14	3.4	Lip, tongue and mouth (C00 -C06)	13	3.0
Colon and rectum (C18 -C20)	14	3.4	Trachea, bronchus and lung (C33 -C34)	12	2.7
Total (All cancers)	387	94.3	Total (All cancers)	449	102.6

North Central Province

Leading cancer incidence data by sex in Anuradhapura District, 2021

Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Lip, tongue and mouth (C00-C06)	78	16.7	Breast (C50)	104	21.3
Trachea, bronchus and lung (C33-C34)	67	14.4	Thyroid (C73)	75	15.4
Oesophagus (C15)	34	7.3	Ovary (C56)	51	10.4
Colon and rectum (C18-C20)	33	7.1	Cervix uteri (C53)	43	8.8
Pharynx (C09-C14)	32	6.9	Colon and rectum (C18-C20)	32	6.6
Prostate (C61)	29	6.2	Uterus (C54-C55)	24	4.9
Bladder (C67)	26	5.6	Leukaemia (C91-C95)	21	4.3
Thyroid (C73)	26	5.6	Oesophagus (C15)	18	3.7
Leukaemia (C91-C95)	25	5.4	Lymphoma (C81-C85, C96)	14	2.9
Stomach (C16)	16	3.4	Lip, tongue and mouth (C00-C06)	13	2.7
Total (All cancers)	493	105.9	Total (All cancers)	483	98.9

Leading cancer incidence data by sex in Polonnaruwa District, 2021

Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Trachea, bronchus and lung (C33-C34)	57	25.7	Breast (C50)	72	31.8
Lip, tongue and mouth (C00-C06)	56	25.3	Thyroid (C73)	63	27.8
Pharynx (C09-C14)	26	11.7	Ovary (C56)	28	12.4
Colon and rectum (C18-C20)	26	11.7	Cervix uteri (C53)	19	8.4
Oesophagus (C15)	24	10.8	Colon and rectum (C18-C20)	18	7.9
Prostate (C61)	23	10.4	Lip, tongue and mouth (C00-C06)	15	6.6
Thyroid (C73)	14	6.3	Uterus (C54-C55)	13	5.7
Lymphoma (C81-C85, C96)	12	5.4	Oesophagus (C15)	13	5.7
Leukaemia (C91-C95)	11	5.0	Trachea, bronchus and lung (C33-C34)	10	4.4
Multiple myeloma (C90)	9	4.1	Leukaemia (C91-C95)	10	4.4
Total (All cancers)	331	149.5	Total (All cancers)	323	142.7

Uva Province

Leading cancer incidence data by sex in Badulla District, 2021

Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Lip, tongue and mouth (C00-C06)	97	22.5	Breast (C50)	95	20.4
Trachea, bronchus and lung (C33-C34)	36	8.4	Oesophagus (C15)	44	9.5
Oesophagus (C15)	33	7.7	Cervix uteri (C53)	39	8.4
Pharynx (C09-C14)	28	6.5	Ovary (C56)	32	6.9
Lymphoma (C81-C85, C96)	24	5.6	Thyroid (C73)	32	6.9
Leukaemia (C91-C95)	24	5.6	Colon and rectum (C18-C20)	25	5.4
Prostate (C61)	17	3.9	Lip, tongue and mouth (C00-C06)	23	4.9
Colon and rectum (C18-C20)	14	3.3	Uterus (C54-C55)	21	4.5
Bladder (C67)	13	3.0	Trachea, bronchus and lung (C33- C34)	15	3.2
Thyroid (C73)	10	2.3	Lymphoma (C81-C85, C96)	15	3.2
Total (All cancers)	372	86.4	Total (All cancers)	417	89.7

Leading cancer incidence data by sex in Monaragala District, 2021

Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Lip, tongue and mouth (C00-C06)	46	18.3	Breast (C50)	63	24.8
Trachea, bronchus and lung (C33-C34)	34	13.5	Thyroid (C73)	37	14.6
Colon and rectum (C18-C20)	21	8.4	Ovary (C56)	23	9.1
Oesophagus (C15)	15	6.0	Cervix uteri (C53)	22	8.7
Prostate (C61)	15	6.0	Colon and rectum (C18-C20)	20	7.9
Leukaemia (C91-C95)	14	5.6	Oesophagus (C15)	15	5.9
Lymphoma (C81-C85, C96)	12	4.8	Lip, tongue and mouth (C00-C06)	13	5.1
Larynx (C32)	10	4.0	Leukaemia (C91-C95)	13	5.1
Pharynx (C09-C14)	8	3.2	Uterus (C54-C55)	9	3.5
Bladder (C67)	7	2.8	Lymphoma (C81-C85, C96)	7	2.8
Total (All cancers)	231	92.0	Total (All cancers)	258	101.5

Sabaragamuwa Province



Leading cancer incidence data by sex in Ratnapura District, 2021



Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Lip, tongue and mouth (C00-C06)	186	31.7	Breast (C50)	191	31.7
Colon and rectum (C18-C20)	57	9.7	Thyroid (C73)	66	10.9
Trachea, bronchus and lung (C33-C34)	52	8.9	Cervix uteri (C53)	66	10.9
Oesophagus (C15)	48	8.2	Ovary (C56)	59	9.8
Pharynx (C09-C14)	37	6.3	Oesophagus (C15)	52	8.6
Lymphoma (C81-C85, C96)	36	6.1	Colon and rectum (C18-C20)	45	7.5
Prostate (C61)	35	6.0	Lip, tongue and mouth (C00-C06)	43	7.1
Larynx (C32)	29	4.9	Uterus (C54-C55)	34	5.6
Multiple myeloma (C90)	24	4.1	Lymphoma (C81-C85, C96)	28	4.6
Leukaemia (C91-C95)	23	3.9	Leukaemia (C91-C95)	26	4.3
Total (All cancers)	674	114.9	Total (All cancers)	772	128.0



Leading cancer incidence data by sex in Kegalle District, 2021



Male			Female		
Site (ICD -10 Code)	No.	CR	Site (ICD -10 Code)	No.	CR
Lip, tongue, and mouth (C00-C06)	97	22.6	Breast (C50)	139	29.6
Oesophagus (C15)	43	10.0	Colon and rectum (C18-C20)	48	10.2
Trachea, bronchus, and lung (C33-C34)	39	9.1	Ovary (C56)	41	8.7
Prostate (C61)	36	8.4	Thyroid (C73)	40	8.5
Pharynx (C09-C14)	31	7.2	Cervix uteri (C53)	37	7.9
Colon and rectum (C18-C20)	30	7.0	Uterus (C54-C55)	29	6.2
Lymphoma (C81-C85, C96)	25	5.8	Oesophagus (C15)	27	5.7
Liver (C22)	20	4.7	Leukaemia (C91-C95)	18	3.8
Leukaemia (C91-C95)	17	4.0	Lip, tongue, and mouth (C00-C06)	16	3.4
Larynx (C32)	14	3.3	Lymphoma (C81-C85, C96)	15	3.2
Total (All cancers)	473	110.4	Total (All cancers)	508	108.0



Figure 60: Cancer Incidence by district among males in 2021























Cancer Mortality Data Sri Lanka - 2021

Introduction

Mortality data due to cancers were obtained through the (i) Department of Census & Statistics website based on data derived from the vital registration system of Sri Lanka, (ii) Annual Health Bulletin of Ministry of Health based on Indoor morbidity mortality return (IMMR) received from government hospital network.

(i) Mortality data through the Vital Registration System

Information on deaths occurred due to cancers throughout the country are obtained through the cause of death data reported to vital registration system of Sri Lanka. This information is published by the Department of Census and Statistics. Cause of death data of year 2019 is the latest available information. (http://www.statistics.gov.lk/Population/Vital_Statistics-2019)

Table 36: Deaths due to neoplasms out of all deaths reported to vital registration system of Sri Lanka 2001 – 2021

Year	Population	Cancer Deaths		
		No.	CDR	PMR (%)
2001	18,797,000	8,063	42.9	7.1
2002	18,921,000	7,986	42.2	7.1
2003	19,173,000	8,396	43.8	7.3
2004	19,435,000	9,127	47.0	7.9
2005	19,644,000	9,403	47.9	7.1
2006	19,958,000	10,386	52.3	8.8
2007	20,039,000	10,631	53.1	8.9
2008*	20,246,000			
2009	20,450,000	11,286	55.2	8.8
2010	20,653,000	11,836	57.3	9.1
2011	20,892,000	12,267	58.7	10.0
2012	20,359,439	12,581	61.8	10.2
2013	20,585,041	12,954	62.9	10.2
2014	20,777,595	13,514	65.0	10.5
2015	20,970,488	13,825	65.9	10.5
2016*	21,202,665			
2017*	21,444,350			
2018*	21,669,511			
2019	21,802,903	15,598	71.5	10.7
2020*	21,919,415			
2021*	22,155,748			

Source: Department of Census & Statistics, Sri Lanka

* Not published

CDR-Crude Death Rate due to cancers per 100,000 population

PMR – Proportionate Mortality Ratio out of total deaths

Table 37: Deaths due to neoplasms by sex out of all deaths reported to vital registration system of Sri Lanka 2001 – 2021

Year	Male			Female		
	No.	CDR	ASDR	No.	CR	ASDR
2001	4375	46.7	52.1	3688	39.1	39.9
2002	4350	46.5	51.2	3636	37.9	38.6
2003	4614	48.7	53.6	3782	38.9	39.6
2004	4942	57.1	57.3	4185	42.9	44.0
2005	4983	50.9	57.0	4420	44.8	45.8
2006	5644	57.1	63.6	4742	47.6	48.7
2007	5827	58.5	65.4	4804	47.6	48.8
2008*						
2009	6105	60.2	67.6	5181	50.3	52.0
2010	6438	62.8	70.9	5398	51.9	53.5
2011	6641	64.0	72.5	5626	53.5	55.3
2012	6908	70.1	65.5	5673	54.0	44.4
2013	7166	71.9	67.4	5788	54.5	44.9
2014	7459	74.2	69.5	6055	56.5	46.5
2015	7726	76.1	71.4	6099	56.4	46.4
2016*						
2017*						
2018*						
2019*	8669	82.1	71.5	6929	61.6	50.6
2020*						
2021*						

Source: Department of Census & Statistics, Sri Lanka

* Not published

CR-Crude annual death rate due to cancers per 100,000 population

ASR – Age standardized annual death rate due to cancers per 100,000 population




Figure 62: Crude Death Rate due to cancers in Sri Lanka Based on Vital Registration System 2001 -2019




Figure 63: Age standardized death rates due to cancer based on Vital Registration system 2001 - 2019

Table 38: Number of deaths and Crude Death Rates due to cancers by sex and site of cancer based on deaths reported to vital registration system of Sri Lanka 2019

ICD- 10 Code	Site of Cancer	Male		Female		Total	
		*No.	**CDR	*No.	**CDR	*No.	**CDR
C00-C14	Lip,oral cavity and pharynx	972	9.2	264	2.4	1,236	5.7
C15	Oesophagus	457	4.3	336	3.0	793	3.6
C16	Stomach	245	2.3	169	1.5	414	1.9
C18-C21	Colon, rectum, and anus	349	3.3	271	2.4	620	2.8
C22	Liver and intrahepatic bile ducts	644	6.1	300	2.7	944	4.3
C25	Pancreas	120	1.1	91	0.8	211	1.0
C32	Larynx	201	1.90	51	0.5	252	1.2
C33-C34	Trachea, bronchus and lung	1,086	10.2	374	3.3	1,460	6.7
C43	Melanoma of skin	3	0.03	5	0.04	8	0.0
C50	Breast	18	0.1	876	7.8	894	4.1
C53	Cervix uteri	0	-	190	1.7	190	-
C54-C55	Uterus	0	-	328	2.9	328	-
C56	Ovary	0	-	289	2.6	289	-
C61	Prostate	267	2.5	0	-	267	-
C67	Bladder	157	1.5	37	0.3	194	0.9
C70-C72	Meninges, brain and other parts of central nervous system	288	2.7	243	2.2	531	2.4
C82-C85	Non-Hodgkin s lymphoma	148	1.4	103	0.9	251	1.2
C90	Multiple myeloma and malignant plasma cell neoplasms	112	1.1	96	0.9	208	1.0
C91-C95	Leukaemia	356	3.4	280	2.5	636	2.9
Other C00 -C95	Remainder of malignant neoplasm	3,161	29.9	2,561	22.8	5,722	26.2
DOO-D48	Remainder of neoplasms D00-D48	85	0.8	65	0.6	150	0.7
COO-D48	All Neoplasms	8,669	77.5	6,929	61.61	15,598	71.5

*No. – Number of deaths, ** CDR – Crude Death Rate




Figure 64: Proportion of leading cancer deaths among males based on deaths reported to vital registration system of Sri Lanka 2019




Figure 65: Proportion of leading cancer deaths among females based on deaths reported to vital registration system of Sri Lanka 2019




Figure 66: Age Standardized Mortality Rates due to cancers of Trachea, bronchus, and lung




Figure 69: Age Standardized Mortality Rates due to cancers of Liver and intrahepatic bile ducts




Figure 67: Age Standardized Mortality Rates due to cancers of Lip, oral cavity, and pharynx




Figure 70: Age Standardized Mortality Rates due to cancers of Oesophagus




Figure 68: Age Standardized Mortality Rates due to cancers of Breast




Figure 71: Age Standardized Mortality Rates due to cancers of Cervix uteri




Figure 72: Age Standardized Mortality Rates due to cancers of Colon, rectum, and anus




Figure 73: Age Standardized Mortality Rates of death due to cancers of Prostate




Figure 74: Breast cancer deaths in each year (2010 to 2019) by age groups




Figure 75: Oral cancer deaths in each year (2010 to 2019) by age groups




Figure 76: Cervical cancer deaths in each year (2010 to 2019) by age groups

(ii) Mortality data through Indoor Morbidity Mortality Return

Mortality data due to cancers were obtained through Annual Health Bulletin of Ministry of Health based on Indoor Morbidity Mortality Return (IMMR)

Table 39: Deaths due to cancers among males & females in hospitals in Sri Lanka, 2005-2021

Year	No. of hospital deaths due to cancers		
	Male	Female	Total
2005			2753
2006			3241
2007			3498
2008			3485
2009			3774
2010			4449
2011			4631
2012	2538	1931	4519
2013	2559	1980	4539
2014	2867	2128	4995
2015	2657	2141	4798
2016	2878	2270	5148
2017	2720	2218	4938
2018	3223	2566	5789
2019	3462	2834	6296
2020	2947	2406	5353
2021	2779	2333	5112

Sources: Annual Health Bulletin 2005 to 2020

Table 40: Deaths due to cancers in hospitals, crude hospital annual death rates due to cancers and proportionate mortality ratio for cancers out of all hospital deaths in Sri Lanka, 2005-2021

Year	No of hospital deaths due to cancers	Crude hospital annual death rate due to cancers per 100,000 population	Proportionate Mortality Ratio PMR out of all hospital deaths
2005	2753	14.0	8.3
2006	3241	16.3	9.9
2007	3498	17.5	10.1
2008	3485	17.2	9.8
2009	3774	18.5	10.0
2010	4449	21.5	11.1
2011	4631	22.2	11.8
2012	4519	22.2	11.6
2013	4539	22.2	11.2
2014	4995	24.0	11.7
2015	4798	22.9	11.0
2016	5148	24.3	12.0
2017	4938	23.0	10.5
2018	5789	26.7	11.7
2019	6296	28.9	11.7
2020	5353	24.4	11.2
2021	5112	23.1	8.0

Sources Annual Health Bulletin 2005 to 2020

Table 41: Hospitalizations, hospital deaths and case fatality rate due to cancers in year 2021 by RDHS divisions in Sri Lanka

RDHS Area	Hospital Admissions due to cancers			** Case fatality rate
	Total hospital admissions	Live hospital discharges	No. hospital deaths	
Colombo	52425	50544	1881	3.6
Gampaha	4096	3841	255	6.2
Kalutara	2171	2124	47	2.2
Kandy	17769	17239	530	3.0
Matale	1534	1467	67	4.4
Nuwara Eliya	1375	1320	55	4.0
Galle	14003	13518	485	3.5
Matara	2938	2865	73	2.5
Hambanthota	2743	2681	62	2.3
Jaffna	3885	3750	135	3.5
Kilinochchi	329	325	4	1.2
Mullaitivu	84	82	2	2.4
Vavuniya	389	365	24	6.2
Mannar	143	142	1	0.7
Batticaloa	586	529	57	9.7
Ampara	499	472	27	5.4
Kalmunai	908	891	17	1.9
Trincomalee	531	512	19	3.6
Kurunegala	5271	4951	320	6.1
Puttalam	982	893	89	9.1
Anuradhapura	6122	5823	299	4.9
Polonnaruwa	1255	1130	125	10.0
Badulla	5207	4956	251	4.8
Monaragala	1099	1049	50	4.5
Ratnapura	6719	6566	153	2.3
Kegalle	847	763	84	9.9
Sri Lanka	133,910	128,798	5,112	3.8

*RDHS area – Regional Director of health Services divisions

**Case Fatality rate = $\frac{\text{No. of hospital deaths due to cancers}}{\text{Total number of hospital admissions due to cancers}} \times 100$

Statistical Terminology

Population at risk

The population at risk includes all individuals susceptible to a specific cancer. It is defined on the basis of demographic variables, such as place of residence, sex, age group. Years of risk duration are counted in person-years.

Incidence

Incidence quantifies the number of new cases that develop in a population of individuals at risk during a specified time interval. Usually, it is given as per 100,000 population per year.

Mortality

Mortality is the number of deaths occurring in a given period in a specified population. It can be expressed as an absolute number of deaths per year or as a rate per 100,000 persons per year.

Crude rate

Data on incidence or mortality are often presented as rates. For a specific tumour and population, a crude rate is calculated simply by dividing the number of cancer deaths observed during a given time period by the corresponding number of person years in the population at risk. For cancer, the result is usually expressed as an annual rate per 100,000 persons at risk.

$$\text{Crude incidence rate} = \frac{\text{Total number of cases in the year}}{\text{Total midyear population at risk}} \times 100,000$$

$$\text{Crude death rate} = \frac{\text{Total number of deaths in the year}}{\text{Total midyear population at risk}} \times 100,000$$

Age-specific rate

The age-specific rate is calculated simply by dividing the number of new cancers or cancer deaths observed in a given age category during a given time period by the corresponding number of person years in the population at risk in the same age category and time period. The result is usually expressed as an annual rate per 100,000 person-years. In this publication, five- year age categories are used

$$\text{Age-specific incidence rate} = \frac{\text{Number of cases in the five-year age group}}{\text{Population at risk in the corresponding age group}} \times 100,000$$

$$\text{Age-specific death rate} = \frac{\text{Number of deaths in the five-year age group}}{\text{Population at risk in the corresponding age group}} \times 100,000$$

ASR (Age standardized rate)

An age-standardised rate (ASR) is a summary measure of the rate that a population would have if it had a standard age structure. Standardization is necessary when comparing several populations that differ with respect to age because age has a powerful influence on the risk of dying from cancer. The ASR is a weighted mean of the age-specific rates; the weights are taken from population distribution of the *standard population*. The most frequently used standard population is the *World Standard Population*. The calculated mortality rate is then called age-standardised mortality rate (world). The world standard population used within the application is as proposed by Segi (1960) and modified by Doll and *al.* (1966). The ASR is also expressed per 100,000.

Age distribution of the world standard population	
Age group	w _i
0-4	12000
5-9	10000
10-14	9000
15-19	9000
20-24	8000
25-29	8000
30-34	6000
35-39	6000
40-44	6000
45-49	6000
50-54	5000
55-59	4000
60-64	4000
65-69	3000
70-74	2000
75-79	1000
80-84	500
85+	500
Total	100000

Life time risk (Cumulative Risk)

Cumulative incidence mortality is the probability or risk of individuals getting dying from the disease within a specified age interval within a time period

The cumulative risk is the risk which an individual would have of developing the cancer under study during a certain age span if no other causes of death were in operation

List of References

Department of Census and Statistics

<http://www.statistics.gov.lk/Population/StatcalInformation/VitalStatistics> [15 November 2023]

Fritz A., Percy C., Jack A., Shanmugaratnam K., Sobin L., Parkin D.M., Whelan S. (ed) (2009) International Classification of Diseases of Oncology, 3rd Edition WHO, Geneva

Glossary of statistical terms; <http://www-dep.iarc.fr/WHOdb/glossary.htm> [20 November 2023]

ICD 10-10th revision, Fifth edition 2016, World Health Organization

International Association of Cancer Registries,

http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=68&Itemid=445

[29 December 2020]

International Classification of Childhood Cancer, Third Edition, *Cancer 2005; 103: 1457-67*

Ministry of Health ,

http://www.health.gov.lk/moh_final/english/public/elfinder/files/publications/AHB/2017/AHB%202015.pdf

[12 October 2023]



NATIONAL CANCER CONTROL PROGRAMME

Ministry of Health

555/5 Public Health Complex
Elvitigala Mawatha, Narahenpita, Colombo 5,
Sri Lanka

+94 11 236 8627

www.nccp.health.gov.lk



9 786246 511043